NK cell-based immunotherapy for malignant diseases
Natural killer （NK） cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current NK cell-based cancer immunotherapy aims to overcome NK cell paralysis using several approaches. One approach uses expa...
Saved in:
| Published in | Cellular & molecular immunology Vol. 10; no. 3; pp. 230 - 252 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
01.05.2013
Nature Publishing Group |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1672-7681 2042-0226 2042-0226 |
| DOI | 10.1038/cmi.2013.10 |
Cover
Loading…
| Abstract | Natural killer （NK） cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current NK cell-based cancer immunotherapy aims to overcome NK cell paralysis using several approaches. One approach uses expanded allogeneic NK cells, which are not inhibited by self histocompatibility antigens like autologous NK cells, for adoptive cellular immunotherapy. Another adoptive transfer approach uses stable allogeneic NK cell lines, which is more practical for quality control and large-scale production. A third approach is genetic modification of fresh NK cells or NK cell lines to highly express cytokines, Fc receptors and/or chimeric tumor-antigen receptors. Therapeutic NK cells can be derived from various sources, including peripheral or cord blood cells, stem cells or even induced pluripotent stem cells （iPSCs）, and a variety of stimulators can be used for large-scale production in laboratories or good manufacturing practice （GMP） facilities, including soluble growth factors, immobilized molecules or antibodies, and other cellular activators. A list of NK cell therapies to treat several types of cancer in clinical trials is reviewed here. Several different approaches to NK-based immunotherapy, such as tissue-specific NK cells, killer receptor-oriented NK cells and chemically treated NK cells, are discussed. A few new techniques or strategies to monitor NK cell therapy by non-invasive imaging, predetermine the efficiency of NK cell therapy by in vivo experiments and evaluate NK cell therapy approaches in clinical trials are also introduced. |
|---|---|
| AbstractList | Natural killer (NK) cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current NK cell-based cancer immunotherapy aims to overcome NK cell paralysis using several approaches. One approach uses expanded allogeneic NK cells, which are not inhibited by self histocompatibility antigens like autologous NK cells, for adoptive cellular immunotherapy. Another adoptive transfer approach uses stable allogeneic NK cell lines, which is more practical for quality control and large-scale production. A third approach is genetic modification of fresh NK cells or NK cell lines to highly express cytokines, Fc receptors and/or chimeric tumor-antigen receptors. Therapeutic NK cells can be derived from various sources, including peripheral or cord blood cells, stem cells or even induced pluripotent stem cells (iPSCs), and a variety of stimulators can be used for large-scale production in laboratories or good manufacturing practice (GMP) facilities, including soluble growth factors, immobilized molecules or antibodies, and other cellular activators. A list of NK cell therapies to treat several types of cancer in clinical trials is reviewed here. Several different approaches to NK-based immunotherapy, such as tissue-specific NK cells, killer receptor-oriented NK cells and chemically treated NK cells, are discussed. A few new techniques or strategies to monitor NK cell therapy by non-invasive imaging, predetermine the efficiency of NK cell therapy by in vivo experiments and evaluate NK cell therapy approaches in clinical trials are also introduced. Natural killer （NK） cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current NK cell-based cancer immunotherapy aims to overcome NK cell paralysis using several approaches. One approach uses expanded allogeneic NK cells, which are not inhibited by self histocompatibility antigens like autologous NK cells, for adoptive cellular immunotherapy. Another adoptive transfer approach uses stable allogeneic NK cell lines, which is more practical for quality control and large-scale production. A third approach is genetic modification of fresh NK cells or NK cell lines to highly express cytokines, Fc receptors and/or chimeric tumor-antigen receptors. Therapeutic NK cells can be derived from various sources, including peripheral or cord blood cells, stem cells or even induced pluripotent stem cells （iPSCs）, and a variety of stimulators can be used for large-scale production in laboratories or good manufacturing practice （GMP） facilities, including soluble growth factors, immobilized molecules or antibodies, and other cellular activators. A list of NK cell therapies to treat several types of cancer in clinical trials is reviewed here. Several different approaches to NK-based immunotherapy, such as tissue-specific NK cells, killer receptor-oriented NK cells and chemically treated NK cells, are discussed. A few new techniques or strategies to monitor NK cell therapy by non-invasive imaging, predetermine the efficiency of NK cell therapy by in vivo experiments and evaluate NK cell therapy approaches in clinical trials are also introduced. Natural killer (NK) cells play critical roles in host immunity against cancer, hi response, cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current NK cell-based cancer immunotherapy aims to overcome NK cell paralysis using several approaches. One approach uses expanded allogeneic NK cells, which are not inhibited by self histocompatibility antigens like autologous NK cells, for adoptive cellular immunotherapy. Another adoptive transfer approach uses stable allogeneic NK cell lines, which is more practical for quality control and large-scale production. A third approach is genetic modification of fresh NK cells or NK cell lines to highly express cytokines, Fc receptors and/or chimeric tumor-antigen receptors. Therapeutic NK cells can be derived from various sources, including peripheral or cord blood cells, stem cells or even induced pluripotent stem cells (iPSCs), and a variety of stimulators can be used for large-scale production in laboratories or good manufacturing practice (GMP) facilities, including soluble growth factors, immobilized molecules or antibodies, and other cellular activators. A list of NK cell therapies to treat several types of cancer in clinical trials is reviewed here. Several different approaches to NK-based immunotherapy, such as tissue-specific NK cells, killer receptor-oriented NK cells and chemically treated NK cells, are discussed. A few new techniques or strategies to monitor NK cell therapy by non-invasive imaging, predetermine the efficiency of NK cell therapy by in vivo experiments and evaluate NK cell therapy approaches in clinical trials are also introduced. Natural killer (NK) cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current NK cell-based cancer immunotherapy aims to overcome NK cell paralysis using several approaches. One approach uses expanded allogeneic NK cells, which are not inhibited by self histocompatibility antigens like autologous NK cells, for adoptive cellular immunotherapy. Another adoptive transfer approach uses stable allogeneic NK cell lines, which is more practical for quality control and large-scale production. A third approach is genetic modification of fresh NK cells or NK cell lines to highly express cytokines, Fc receptors and/or chimeric tumor-antigen receptors. Therapeutic NK cells can be derived from various sources, including peripheral or cord blood cells, stem cells or even induced pluripotent stem cells (iPSCs), and a variety of stimulators can be used for large-scale production in laboratories or good manufacturing practice (GMP) facilities, including soluble growth factors, immobilized molecules or antibodies, and other cellular activators. A list of NK cell therapies to treat several types of cancer in clinical trials is reviewed here. Several different approaches to NK-based immunotherapy, such as tissue-specific NK cells, killer receptor-oriented NK cells and chemically treated NK cells, are discussed. A few new techniques or strategies to monitor NK cell therapy by non-invasive imaging, predetermine the efficiency of NK cell therapy by in vivo experiments and evaluate NK cell therapy approaches in clinical trials are also introduced.Natural killer (NK) cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current NK cell-based cancer immunotherapy aims to overcome NK cell paralysis using several approaches. One approach uses expanded allogeneic NK cells, which are not inhibited by self histocompatibility antigens like autologous NK cells, for adoptive cellular immunotherapy. Another adoptive transfer approach uses stable allogeneic NK cell lines, which is more practical for quality control and large-scale production. A third approach is genetic modification of fresh NK cells or NK cell lines to highly express cytokines, Fc receptors and/or chimeric tumor-antigen receptors. Therapeutic NK cells can be derived from various sources, including peripheral or cord blood cells, stem cells or even induced pluripotent stem cells (iPSCs), and a variety of stimulators can be used for large-scale production in laboratories or good manufacturing practice (GMP) facilities, including soluble growth factors, immobilized molecules or antibodies, and other cellular activators. A list of NK cell therapies to treat several types of cancer in clinical trials is reviewed here. Several different approaches to NK-based immunotherapy, such as tissue-specific NK cells, killer receptor-oriented NK cells and chemically treated NK cells, are discussed. A few new techniques or strategies to monitor NK cell therapy by non-invasive imaging, predetermine the efficiency of NK cell therapy by in vivo experiments and evaluate NK cell therapy approaches in clinical trials are also introduced. Natural killer (NK) cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current NK cell-based cancer immunotherapy aims to overcome NK cell paralysis using several approaches. One approach uses expanded allogeneic NK cells, which are not inhibited by self histocompatibility antigens like autologous NK cells, for adoptive cellular immunotherapy. Another adoptive transfer approach uses stable allogeneic NK cell lines, which is more practical for quality control and large-scale production. A third approach is genetic modification of fresh NK cells or NK cell lines to highly express cytokines, Fc receptors and/or chimeric tumor-antigen receptors. Therapeutic NK cells can be derived from various sources, including peripheral or cord blood cells, stem cells or even induced pluripotent stem cells (iPSCs), and a variety of stimulators can be used for large-scale production in laboratories or good manufacturing practice (GMP) facilities, including soluble growth factors, immobilized molecules or antibodies, and other cellular activators. A list of NK cell therapies to treat several types of cancer in clinical trials is reviewed here. Several different approaches to NK-based immunotherapy, such as tissue-specific NK cells, killer receptor-oriented NK cells and chemically treated NK cells, are discussed. A few new techniques or strategies to monitor NK cell therapy by non-invasive imaging, predetermine the efficiency of NK cell therapy by in vivo experiments and evaluate NK cell therapy approaches in clinical trials are also introduced. |
| Author | Min Cheng Yongyan Chen Weihua Xiao Rui Sun Zhigang Tian |
| AuthorAffiliation | Institute of Immunology, University of Science and Technology of China, Hefei, China |
| Author_xml | – sequence: 1 givenname: Min surname: Cheng fullname: Cheng, Min organization: Institute of Immunology, University of Science and Technology of China – sequence: 2 givenname: Yongyan surname: Chen fullname: Chen, Yongyan organization: Institute of Immunology, University of Science and Technology of China – sequence: 3 givenname: Weihua surname: Xiao fullname: Xiao, Weihua organization: Institute of Immunology, University of Science and Technology of China – sequence: 4 givenname: Rui surname: Sun fullname: Sun, Rui organization: Institute of Immunology, University of Science and Technology of China – sequence: 5 givenname: Zhigang surname: Tian fullname: Tian, Zhigang email: tzg@ustc.edu.cn organization: Institute of Immunology, University of Science and Technology of China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23604045$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkkFv1DAQhS1URLcLJ-4oiAsSpNgzdpxckFDVAqKCC5wtx3F2XSX21k6Q-u9xtNuqVBWcrJG_eZo3807IkQ_eEvKS0VNGsf5gRncKlGGunpAVUA4lBaiOyIpVEkpZ1eyYnKR0RamoueTPyDFgRTnlYkXg-7fC2GEoW51sV7hxnH2Ytjbq3U3Rh1iMenAbr_1UdC7ZDKXn5Gmvh2RfHN41-XVx_vPsS3n54_PXs0-XpRGIUwm90K01YG3XYI-ylQI4bzqBAsEw1Jb2uu1Q6q6RQHvsemGqxkJjesZbg2vyca-7m9vRdsb6KepB7aIbdbxRQTv19493W7UJvxWnspJYZ4G3B4EYrmebJjW6tJjV3oY5KcaRU6yA4v9R5A1toEaW0TcP0KswR583oUBW-SCCifpfFJO1EIxRaDL16r7FO2-398kA2wMmhpSi7ZVxk55cWBy7QTGqlgyonAG1ZGCp1uTdg55b2cfp93s6ZcpvbLw36KP464P4NvjNde64U-cVA7Hs_Q8GHsp2 |
| CitedBy_id | crossref_primary_10_3389_fimmu_2015_00264 crossref_primary_10_1016_j_tibtech_2014_10_006 crossref_primary_10_1016_j_smim_2020_101407 crossref_primary_10_3389_fimmu_2022_861681 crossref_primary_10_1002_bip_22879 crossref_primary_10_1016_j_imlet_2020_11_003 crossref_primary_10_1371_journal_pone_0212455 crossref_primary_10_1189_jlb_5VMR0415_141R crossref_primary_10_1002_cbin_11465 crossref_primary_10_3390_v9100295 crossref_primary_10_1016_j_jtho_2018_01_017 crossref_primary_10_1016_j_ucl_2020_10_005 crossref_primary_10_1002_stem_2780 crossref_primary_10_1016_j_eng_2018_11_015 crossref_primary_10_1007_s00262_015_1744_y crossref_primary_10_1016_j_imlet_2014_05_004 crossref_primary_10_1016_j_bbmt_2020_09_030 crossref_primary_10_3390_biom11081066 crossref_primary_10_1155_2021_9919422 crossref_primary_10_3389_fonc_2022_1062765 crossref_primary_10_1016_j_clim_2016_02_003 crossref_primary_10_1038_s41577_019_0139_2 crossref_primary_10_1080_08923973_2020_1742733 crossref_primary_10_1016_j_intimp_2014_01_012 crossref_primary_10_1016_j_reval_2024_104160 crossref_primary_10_1016_j_xcrp_2024_102339 crossref_primary_10_1016_j_bbcan_2014_07_005 crossref_primary_10_1002_jcp_28280 crossref_primary_10_1007_s00262_017_2112_x crossref_primary_10_1073_pnas_1519079112 crossref_primary_10_1038_ncomms11154 crossref_primary_10_1186_s13046_020_01778_6 crossref_primary_10_1038_s41591_022_02003_x crossref_primary_10_3390_jcm9103237 crossref_primary_10_1038_s41565_024_01736_9 crossref_primary_10_3390_biomedicines9060662 crossref_primary_10_3389_fendo_2022_1089918 crossref_primary_10_4161_21624011_2014_955441 crossref_primary_10_1016_j_mcp_2022_101817 crossref_primary_10_3390_cancers13081988 crossref_primary_10_3390_cells11213469 crossref_primary_10_23868_gc120507 crossref_primary_10_1007_s11684_018_0621_4 crossref_primary_10_1038_s41598_019_51287_6 crossref_primary_10_15825_1995_1191_2018_3_95_104 crossref_primary_10_1371_journal_pone_0157830 crossref_primary_10_1016_j_clim_2016_11_010 crossref_primary_10_1111_aji_13355 crossref_primary_10_2217_fon_2017_0039 crossref_primary_10_3389_fimmu_2014_00534 crossref_primary_10_3390_futurepharmacol2040039 crossref_primary_10_1186_s12865_018_0262_z crossref_primary_10_1038_srep21678 crossref_primary_10_1074_jbc_M114_603464 crossref_primary_10_12677_jcpm_2024_34324 crossref_primary_10_3892_mmr_2014_1975 crossref_primary_10_1007_s00262_017_1969_z crossref_primary_10_1016_j_cellsig_2024_111405 crossref_primary_10_1016_j_peptides_2017_05_006 crossref_primary_10_1038_s41598_019_45377_8 crossref_primary_10_1155_2014_326545 crossref_primary_10_1007_s11427_017_9128_3 crossref_primary_10_2478_fco_2021_0006 crossref_primary_10_1186_s13287_021_02462_y crossref_primary_10_3390_cancers8080071 crossref_primary_10_3390_cells10030543 crossref_primary_10_1016_j_imlet_2018_04_003 crossref_primary_10_1177_03008916211070051 crossref_primary_10_1146_annurev_cancerbio_030518_055653 crossref_primary_10_1371_journal_pone_0191358 crossref_primary_10_3390_jcm9082418 crossref_primary_10_1631_jzus_B1800421 crossref_primary_10_1016_j_ijbiomac_2018_11_200 crossref_primary_10_1002_ajh_25983 crossref_primary_10_1016_j_ejphar_2023_176106 crossref_primary_10_3390_cancers12082226 crossref_primary_10_1080_14647273_2016_1219072 crossref_primary_10_3390_ijms22105120 crossref_primary_10_1016_j_jcyt_2015_03_611 crossref_primary_10_1002_cyto_b_21500 crossref_primary_10_1080_2162402X_2016_1143996 crossref_primary_10_1080_08830185_2020_1845670 crossref_primary_10_3389_fimmu_2017_00892 crossref_primary_10_1007_s12094_023_03120_w crossref_primary_10_1002_eji_201445209 crossref_primary_10_1080_2162402X_2016_1160184 crossref_primary_10_1007_s12026_017_8927_x crossref_primary_10_1002_adma_201907568 crossref_primary_10_3389_fimmu_2017_00625 crossref_primary_10_1016_j_canlet_2019_08_018 crossref_primary_10_3390_cancers12082131 crossref_primary_10_1186_s13075_019_2054_0 crossref_primary_10_1080_2162402X_2017_1395123 crossref_primary_10_1007_s10238_023_01177_z crossref_primary_10_1016_j_imlet_2017_03_018 crossref_primary_10_1155_2016_5230219 crossref_primary_10_3389_fimmu_2014_00439 crossref_primary_10_1038_s41423_021_00808_3 crossref_primary_10_1007_s12026_024_09573_7 crossref_primary_10_1016_j_clim_2017_12_003 crossref_primary_10_1038_s41423_021_00786_6 crossref_primary_10_4049_jimmunol_1600581 crossref_primary_10_1007_s11684_018_0653_9 crossref_primary_10_1007_s43188_022_00138_0 crossref_primary_10_1038_aps_2015_41 crossref_primary_10_2217_imt_15_65 crossref_primary_10_1021_acsnano_1c02103 crossref_primary_10_1073_pnas_1710756114 crossref_primary_10_1007_s11033_014_3514_x crossref_primary_10_1182_blood_2016_02_698027 crossref_primary_10_3390_cells9071578 crossref_primary_10_1002_adhm_202403477 crossref_primary_10_3892_ol_2017_7365 crossref_primary_10_1172_JCI83005 crossref_primary_10_1186_s12865_018_0272_x crossref_primary_10_1039_D4MA00427B crossref_primary_10_1016_j_intimp_2021_107409 crossref_primary_10_1016_j_jss_2016_11_058 crossref_primary_10_3389_fonc_2021_649710 crossref_primary_10_1016_j_imlet_2017_03_004 crossref_primary_10_1016_j_it_2014_11_001 crossref_primary_10_3390_cancers11070967 crossref_primary_10_1016_j_ijrobp_2023_11_023 crossref_primary_10_1016_j_molimm_2017_10_003 crossref_primary_10_1021_acs_jmedchem_7b00901 crossref_primary_10_2967_jnumed_114_152918 crossref_primary_10_1155_2013_430290 crossref_primary_10_1016_j_bbcan_2018_01_005 crossref_primary_10_4110_in_2015_15_3_135 crossref_primary_10_1016_j_yexcr_2018_01_041 crossref_primary_10_3389_fimmu_2019_01205 crossref_primary_10_18632_oncotarget_1919 crossref_primary_10_30773_pi_2017_11_10 crossref_primary_10_3389_fimmu_2021_616853 crossref_primary_10_1080_15384047_2016_1177678 crossref_primary_10_3389_fimmu_2017_00280 crossref_primary_10_1186_s12935_024_03211_w crossref_primary_10_1016_j_intimp_2022_108783 crossref_primary_10_1016_j_imlet_2017_09_004 crossref_primary_10_18632_oncotarget_14260 crossref_primary_10_1002_advs_202103245 crossref_primary_10_1016_j_ejmech_2020_113043 crossref_primary_10_1016_j_intimp_2024_112233 crossref_primary_10_2217_nnm_15_24 crossref_primary_10_1016_j_carbpol_2016_08_086 crossref_primary_10_1111_cas_15958 crossref_primary_10_1016_j_clim_2015_10_001 crossref_primary_10_2217_imt_2018_0002 crossref_primary_10_1142_S0192415X19500435 crossref_primary_10_1016_j_carbpol_2020_117250 crossref_primary_10_1053_j_seminhematol_2019_11_003 crossref_primary_10_1158_1078_0432_CCR_17_0691 crossref_primary_10_5045_br_2018_53_3_198 crossref_primary_10_1002_cac2_12121 crossref_primary_10_3389_fimmu_2024_1317522 crossref_primary_10_1186_s40425_016_0184_3 crossref_primary_10_1016_j_canlet_2021_03_009 crossref_primary_10_18632_oncotarget_27242 crossref_primary_10_1002_adhm_202102080 crossref_primary_10_1016_j_biomaterials_2021_121058 crossref_primary_10_1155_2015_732438 crossref_primary_10_1016_j_ygyno_2022_03_013 crossref_primary_10_18632_oncotarget_18659 crossref_primary_10_1155_2015_734731 crossref_primary_10_1186_s13287_021_02251_7 crossref_primary_10_1038_srep41381 crossref_primary_10_4110_in_2020_20_e14 crossref_primary_10_1158_1940_6207_CAPR_17_0046 crossref_primary_10_1016_j_jtbi_2016_06_012 crossref_primary_10_1016_j_cytogfr_2024_02_001 crossref_primary_10_3389_fphar_2019_00898 crossref_primary_10_1126_scitranslmed_aad7118 crossref_primary_10_3389_fimmu_2015_00578 crossref_primary_10_3389_fimmu_2020_00331 crossref_primary_10_1371_journal_pone_0142767 crossref_primary_10_1007_s00262_023_03503_6 crossref_primary_10_1007_s00262_015_1786_1 crossref_primary_10_1016_j_smim_2014_02_002 crossref_primary_10_1038_aps_2017_125 crossref_primary_10_1089_jmf_2018_4286 crossref_primary_10_1016_j_smim_2017_07_009 crossref_primary_10_1016_j_stem_2018_06_002 crossref_primary_10_3390_cancers11091375 crossref_primary_10_1016_j_cca_2019_12_030 crossref_primary_10_1016_j_smim_2017_07_011 crossref_primary_10_1016_j_ymthe_2017_08_010 crossref_primary_10_1016_j_canlet_2023_216328 crossref_primary_10_1038_cmi_2013_5 crossref_primary_10_1016_j_intimp_2013_12_011 crossref_primary_10_1016_j_addr_2023_114865 crossref_primary_10_1186_s40824_023_00403_9 crossref_primary_10_1002_JLB_MA0618_231R crossref_primary_10_1021_acsnano_0c03824 crossref_primary_10_1016_j_intimp_2021_108220 crossref_primary_10_3389_fimmu_2017_01212 crossref_primary_10_1038_leu_2014_174 crossref_primary_10_1186_s12967_022_03437_0 crossref_primary_10_3389_fimmu_2015_00230 crossref_primary_10_3389_fmicb_2017_00495 crossref_primary_10_3390_ijms22189975 crossref_primary_10_1155_2019_4564213 crossref_primary_10_1016_j_transci_2021_103065 crossref_primary_10_1182_blood_2021013972 crossref_primary_10_1016_j_medcle_2019_08_004 crossref_primary_10_34172_ia_4080 crossref_primary_10_1002_adbi_202000298 crossref_primary_10_1016_j_medcli_2019_08_008 crossref_primary_10_1016_j_mehy_2017_10_015 crossref_primary_10_1021_acsabm_1c00461 crossref_primary_10_1002_biot_202300654 crossref_primary_10_18632_oncotarget_18423 crossref_primary_10_1186_s43042_025_00670_2 crossref_primary_10_3389_fimmu_2016_00016 crossref_primary_10_1007_s43440_021_00335_y crossref_primary_10_1371_journal_pone_0247612 crossref_primary_10_1016_j_jcyt_2015_09_011 crossref_primary_10_1016_j_trsl_2015_07_008 crossref_primary_10_3389_fimmu_2021_619195 crossref_primary_10_1186_s43556_024_00212_z crossref_primary_10_3389_fphar_2019_00326 crossref_primary_10_3892_ol_2016_4835 crossref_primary_10_1016_j_jcyt_2019_07_004 crossref_primary_10_1038_srep32470 crossref_primary_10_3389_fimmu_2021_737340 crossref_primary_10_1002_btpr_3464 crossref_primary_10_3390_cancers11060769 crossref_primary_10_1038_cmi_2015_96 crossref_primary_10_1186_s13287_024_04125_0 crossref_primary_10_1517_14712598_2015_1069272 crossref_primary_10_1016_j_tibtech_2022_06_011 crossref_primary_10_1038_505483e crossref_primary_10_1093_carcin_bgw115 crossref_primary_10_1186_s13059_021_02280_8 crossref_primary_10_1186_s13046_018_0952_7 crossref_primary_10_18632_oncotarget_21974 crossref_primary_10_1016_j_ymthe_2025_02_013 crossref_primary_10_1186_s12885_019_6145_8 crossref_primary_10_1007_s00262_016_1919_1 crossref_primary_10_1073_pnas_1516373112 crossref_primary_10_1016_j_bioactmat_2023_08_001 crossref_primary_10_1186_s13045_020_00998_9 crossref_primary_10_3390_ijms161226238 crossref_primary_10_1186_s13058_022_01568_2 crossref_primary_10_1080_2162402X_2015_1036212 crossref_primary_10_1038_leu_2013_279 crossref_primary_10_1080_21645515_2015_1009814 crossref_primary_10_1021_acsnano_1c01889 crossref_primary_10_1002_cam4_1459 crossref_primary_10_3389_fimmu_2016_00235 crossref_primary_10_1016_j_tcb_2015_10_005 crossref_primary_10_1016_j_cryobiol_2019_01_004 crossref_primary_10_1038_srep29889 crossref_primary_10_1080_1354750X_2021_2016973 crossref_primary_10_1016_j_canlet_2015_04_010 crossref_primary_10_1007_s11033_022_07865_5 crossref_primary_10_1016_j_lfs_2021_119110 crossref_primary_10_1080_08830185_2017_1284209 crossref_primary_10_2174_1566523222666211217091724 crossref_primary_10_3389_fimmu_2017_01095 crossref_primary_10_1039_C9NR08086D crossref_primary_10_1016_j_ijsu_2016_04_052 crossref_primary_10_1007_s12010_016_2187_4 crossref_primary_10_1016_j_jconrel_2014_03_050 crossref_primary_10_18632_oncotarget_19445 crossref_primary_10_2174_1872212115666210625150220 crossref_primary_10_1089_jir_2021_0078 crossref_primary_10_1021_acs_molpharmaceut_2c00557 crossref_primary_10_1016_j_biopha_2023_115104 crossref_primary_10_1002_cbic_202000407 crossref_primary_10_1016_j_heliyon_2024_e33928 crossref_primary_10_1002_iub_2180 crossref_primary_10_1186_s12885_015_2034_y crossref_primary_10_62347_IARO1564 crossref_primary_10_3892_or_2021_8183 crossref_primary_10_1039_C8BM00588E crossref_primary_10_1021_acs_bioconjchem_5b00139 crossref_primary_10_1038_nrrheum_2016_140 crossref_primary_10_1007_s00432_018_2654_0 crossref_primary_10_1016_j_cbi_2018_11_013 crossref_primary_10_3390_cancers16132446 crossref_primary_10_3389_fimmu_2016_00694 crossref_primary_10_3389_fimmu_2018_01409 crossref_primary_10_3389_fimmu_2023_1275904 crossref_primary_10_1016_j_gpb_2020_12_003 crossref_primary_10_1080_2162402X_2014_1002720 crossref_primary_10_3892_ol_2016_5055 crossref_primary_10_3389_fphar_2020_566401 crossref_primary_10_1039_C5AN02585K crossref_primary_10_1097_CJI_0000000000000179 crossref_primary_10_3390_ijms151120209 crossref_primary_10_1038_s41423_020_0515_7 crossref_primary_10_1111_ijlh_12594 crossref_primary_10_1016_j_yexcr_2024_113933 crossref_primary_10_3389_fimmu_2017_01090 crossref_primary_10_1016_j_prp_2022_154295 crossref_primary_10_1007_s10527_022_10175_6 crossref_primary_10_3389_fimmu_2018_01990 crossref_primary_10_3389_fimmu_2020_00060 crossref_primary_10_1515_psr_2019_0058 crossref_primary_10_2217_imt_2015_0024 crossref_primary_10_1016_j_jcyt_2015_01_004 crossref_primary_10_1098_rsif_2017_0105 crossref_primary_10_1111_imm_12494 crossref_primary_10_1146_annurev_immunol_032414_112043 crossref_primary_10_1097_MD_0000000000024272 crossref_primary_10_3390_vaccines10091493 crossref_primary_10_1016_j_intimp_2022_108580 crossref_primary_10_1182_blood_2014_04_569061 crossref_primary_10_1002_aac2_12032 crossref_primary_10_1016_j_isci_2020_101454 crossref_primary_10_1007_s00535_014_1000_9 crossref_primary_10_1002_adma_202301770 crossref_primary_10_3389_fimmu_2017_00087 crossref_primary_10_1002_jcp_26878 crossref_primary_10_1016_j_clon_2022_10_019 crossref_primary_10_1242_dmm_018036 crossref_primary_10_1002_jev2_12387 crossref_primary_10_1007_s00262_016_1806_9 crossref_primary_10_1016_j_critrevonc_2014_08_003 crossref_primary_10_1186_s13045_020_00996_x crossref_primary_10_1186_s13058_015_0588_x crossref_primary_10_1007_s00262_014_1614_z crossref_primary_10_3390_jpm11080697 crossref_primary_10_1097_CJI_0000000000000192 crossref_primary_10_3389_fphar_2023_1263834 crossref_primary_10_3390_vaccines9111363 crossref_primary_10_1007_s10522_018_9757_5 crossref_primary_10_3390_cancers11040515 crossref_primary_10_1038_s41467_019_08538_x crossref_primary_10_1128_CMR_00105_13 crossref_primary_10_1186_s13046_024_03173_x crossref_primary_10_1038_srep43873 crossref_primary_10_1007_s00262_022_03161_0 crossref_primary_10_1038_cddis_2017_158 crossref_primary_10_1038_onc_2015_324 crossref_primary_10_3389_fimmu_2022_1081546 crossref_primary_10_3389_fgene_2022_848841 crossref_primary_10_1158_2326_6066_CIR_16_0162 crossref_primary_10_7314_APJCP_2015_16_17_7837 crossref_primary_10_3390_bioengineering7020059 crossref_primary_10_1021_acs_molpharmaceut_0c00271 crossref_primary_10_18632_oncotarget_19373 crossref_primary_10_3389_fimmu_2022_890894 crossref_primary_10_1016_j_biopha_2024_117726 crossref_primary_10_1016_j_biopha_2021_111875 crossref_primary_10_1155_2022_9218640 crossref_primary_10_1007_s00432_016_2247_8 crossref_primary_10_1080_14712598_2018_1402002 crossref_primary_10_1097_QAD_0000000000001645 crossref_primary_10_1177_1753425919846584 crossref_primary_10_1007_s10517_016_3496_x crossref_primary_10_1111_imcb_12658 crossref_primary_10_1016_j_canlet_2015_06_029 crossref_primary_10_3390_ijms18091797 crossref_primary_10_1074_jbc_M115_674010 crossref_primary_10_1080_2162402X_2016_1211220 crossref_primary_10_1158_1078_0432_CCR_16_0184 crossref_primary_10_1080_21678707_2017_1304212 crossref_primary_10_5483_BMBRep_2021_54_1_214 crossref_primary_10_1002_mco2_626 crossref_primary_10_15430_JCP_2017_22_4_260 crossref_primary_10_3389_fmed_2015_00093 crossref_primary_10_1111_jdv_13246 crossref_primary_10_2217_imt_2016_0009 crossref_primary_10_1016_j_ctrv_2018_09_007 crossref_primary_10_1038_s43018_023_00624_w crossref_primary_10_1016_j_canlet_2014_12_020 crossref_primary_10_33821_213 crossref_primary_10_19127_bshealthscience_1009193 crossref_primary_10_1186_s13045_020_00913_2 crossref_primary_10_2174_1871525720666220829142225 crossref_primary_10_3390_curroncol28020105 crossref_primary_10_2174_1876401001807010007 crossref_primary_10_1039_C7LC00963A crossref_primary_10_1016_j_immuni_2017_11_018 crossref_primary_10_1038_cmi_2014_30 crossref_primary_10_18632_oncotarget_6939 crossref_primary_10_1002_pbc_27783 crossref_primary_10_1186_s12935_018_0624_x crossref_primary_10_3389_fimmu_2020_575609 crossref_primary_10_3390_biomedicines12010183 crossref_primary_10_1051_medsci_20183406013 crossref_primary_10_1016_j_gine_2023_100928 crossref_primary_10_1155_2019_6032141 crossref_primary_10_18632_oncotarget_25506 crossref_primary_10_1002_btm2_10214 crossref_primary_10_1038_s41467_020_16447_7 crossref_primary_10_1007_s12026_015_8695_4 crossref_primary_10_1007_s12154_016_0164_6 crossref_primary_10_1016_j_intimp_2021_107837 crossref_primary_10_3389_fonc_2022_834002 crossref_primary_10_3390_biomedicines11061768 crossref_primary_10_1016_j_jpba_2021_113981 crossref_primary_10_1016_j_intimp_2021_107714 crossref_primary_10_1134_S1990519X20050090 crossref_primary_10_3389_fonc_2016_00054 crossref_primary_10_18632_oncotarget_10375 crossref_primary_10_1517_14712598_2015_1036735 crossref_primary_10_1016_j_bbrc_2022_11_090 crossref_primary_10_1186_s12916_016_0715_2 crossref_primary_10_1002_cbdv_202400806 crossref_primary_10_3389_fimmu_2018_03095 crossref_primary_10_1080_1744666X_2021_1911648 crossref_primary_10_1007_s12026_023_09410_3 crossref_primary_10_2217_fon_2020_1013 crossref_primary_10_1097_CJI_0000000000000227 crossref_primary_10_1111_cas_12819 crossref_primary_10_3390_cancers11040461 crossref_primary_10_1002_jcp_28785 crossref_primary_10_1002_jcp_28421 crossref_primary_10_1016_j_canlet_2016_01_001 crossref_primary_10_1038_s41598_017_09259_1 crossref_primary_10_3390_antib5010001 crossref_primary_10_1038_s41598_017_08483_z crossref_primary_10_1002_jcp_28657 crossref_primary_10_1016_j_cryobiol_2020_02_010 crossref_primary_10_1146_annurev_bioeng_062117_120947 crossref_primary_10_18632_oncotarget_19193 crossref_primary_10_1155_2014_525913 crossref_primary_10_3389_fimmu_2023_1147718 crossref_primary_10_3389_fcell_2024_1435484 crossref_primary_10_3390_cancers12051153 crossref_primary_10_2147_ITT_S306109 crossref_primary_10_15616_BSL_2015_21_4_172 crossref_primary_10_2174_1568009620666200504111914 crossref_primary_10_1007_s00432_017_2513_4 crossref_primary_10_1038_cmi_2014_114 crossref_primary_10_1186_s13073_024_01320_9 crossref_primary_10_1016_j_intimp_2023_110669 crossref_primary_10_1016_j_humimm_2017_01_003 crossref_primary_10_3389_fimmu_2017_00930 crossref_primary_10_1080_2162402X_2016_1219007 crossref_primary_10_1002_eji_201444998 crossref_primary_10_1080_2162402X_2017_1303586 crossref_primary_10_1155_2015_308574 crossref_primary_10_18632_oncotarget_23488 crossref_primary_10_1007_s12016_013_8400_0 crossref_primary_10_1016_j_canlet_2017_03_035 crossref_primary_10_1016_j_ijbiomac_2017_01_108 crossref_primary_10_2217_imt_2019_0040 crossref_primary_10_1111_bjh_14595 crossref_primary_10_1186_s13058_017_0867_9 crossref_primary_10_21294_1814_4861_2018_17_6_97_104 crossref_primary_10_18632_oncotarget_17804 crossref_primary_10_1186_s12865_023_00591_y crossref_primary_10_1089_cbr_2019_3141 crossref_primary_10_1016_j_neo_2017_02_014 crossref_primary_10_3389_fimmu_2020_00812 crossref_primary_10_1002_mc_23042 crossref_primary_10_3389_fimmu_2024_1498942 crossref_primary_10_1136_jitc_2020_001740 crossref_primary_10_1186_s40880_019_0379_3 crossref_primary_10_1016_j_vetimm_2019_03_005 crossref_primary_10_18632_oncotarget_12466 crossref_primary_10_3390_pharmaceutics16070939 crossref_primary_10_1016_j_oraloncology_2022_105777 crossref_primary_10_1039_D1LC00651G |
| Cites_doi | 10.1016/S0065-230X(06)95008-8 10.1016/0959-8049(94)90460-X 10.1016/j.immuni.2006.06.013 10.1038/sj.leu.2401769 10.1007/s00259-003-1398-4 10.3109/14653249.2010.504770 10.1016/0167-5699(90)90097-S 10.1084/jem.20051511 10.1046/j.1365-2141.2001.03055.x 10.2310/7290.2009.00002 10.1084/jem.162.6.1745 10.1158/1078-0432.CCR-04-0265 10.1016/S0065-2776(04)86006-1 10.1038/35105075 10.1084/jem.20010934 10.1016/S0065-2776(08)60387-9 10.1111/j.1748-5827.2002.tb00015.x 10.1080/14653240802301872 10.1038/ni746 10.1073/pnas.191362598 10.1038/cmi.2011.23 10.1158/0008-5472.CAN-08-3712 10.1016/j.biomaterials.2010.10.013 10.1002/eji.1830251246 10.1038/nrclinonc.2011.141 10.1038/nri2073 10.1016/S0065-230X(08)60936-7 10.1007/s00262-008-0492-7 10.3109/14653249.2010.515582 10.1038/sj.leu.2401145 10.1158/0008-5472.CAN-08-2268 10.1007/s11684-012-0177-7 10.3109/14653249.2012.700767 10.1007/s00330-008-0984-z 10.1038/nrc928 10.1002/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z 10.1084/jem.193.6.661 10.1038/sj.cgt.7700453 10.1038/cmi.2011.20 10.1016/j.pain.2010.01.024 10.1016/S0301-472X(01)00696-8 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V 10.1111/j.1365-2141.2004.05286.x 10.1016/j.bcmd.2007.06.029 10.1007/BF00915064 10.1016/j.jaut.2009.07.010 10.1158/1078-0432.CCR-05-0577 10.1016/j.coi.2009.07.015 10.1038/onc.2008.267 10.1089/15258160152509145 10.1073/pnas.050588297 10.1007/s00262-011-1050-2 10.1073/pnas.93.4.1453 10.1517/14712598.5.2.163 10.1080/14653240310001523 10.1016/j.humimm.2006.02.008 10.1038/358066a0 10.1080/10408360902937809 10.1189/jlb.0710422 10.4049/jimmunol.171.2.608 10.1089/scd.2007.0033 10.1371/journal.pone.0030264 10.1182/blood-2006-05-024315 10.1146/annurev.immunol.24.021605.090700 10.1038/nri3044 10.1038/319675a0 10.1056/NEJM198512053132327 10.1182/blood.V99.4.1259 10.1126/science.7716543 10.1038/35095564 10.1007/s005990050079 10.1038/35040504 10.1182/blood.V97.1.192 10.1182/blood-2011-01-329508 10.1038/nri1603 10.1016/S1359-6446(03)02955-6 10.1158/1078-0432.CCR-03-0683 10.1016/S0140-6736(00)03231-1 10.4049/jimmunol.180.9.6392 10.4049/jimmunol.169.8.4098 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P 10.4049/jimmunol.172.4.2048 10.1182/blood-2008-10-182048 10.1182/blood-2009-03-191304 10.1016/j.bbmt.2010.02.018 10.1111/j.1600-065X.2006.00457.x 10.1038/nri3065 10.1002/(SICI)1521-4141(199904)29:04<1390::AID-IMMU1390>3.0.CO;2-C 10.1111/j.1399-0039.2010.01535.x 10.1007/s00262-010-0904-3 10.1016/j.cyto.2008.01.003 10.1182/blood-2010-08-301945 10.1111/j.1365-2796.2009.02121.x 10.1158/1078-0432.CCR-11-1347 10.1073/pnas.0901653106 10.1016/S0952-7915(00)00094-7 10.1371/journal.pone.0020740 10.1016/S1074-7613(03)00264-4 10.4049/jimmunol.167.4.2068 10.1016/S1054-3589(04)51013-X 10.1371/journal.pone.0009221 10.1182/blood.V99.10.3661 10.1080/09553000600649653 10.1002/ijc.2910250409 10.1016/j.semcancer.2005.11.005 10.1084/jem.20010938 10.1097/01.cji.0000161395.88959.1f 10.1002/eji.1830050208 10.1016/j.exphem.2004.11.003 10.1186/1756-9966-29-134 10.1097/CJI.0b013e3181ab23f1 10.1016/S0065-230X(03)90004-2 10.1016/j.leukres.2004.07.005 10.1089/10430349950018030 10.1159/000282651 10.1172/JCI0215950 10.1038/83416 10.1182/blood-2005-03-1154 10.4049/jimmunol.168.3.1356 10.1126/science.1068440 10.1155/2011/379123 10.1158/0008-5472.CAN-05-2520 10.1158/0008-5472.CAN-09-3774 10.4049/jimmunol.172.3.1333 10.1517/14712598.2.1.35 10.1182/blood-2004-07-2974 10.1080/14653240902807034 10.1038/ni1138 10.1002/1097-0142(19950901)76:5<840::AID-CNCR2820760519>3.0.CO;2-R 10.1182/blood-2009-02-206532 10.1016/j.ejphar.2009.09.067 10.1016/S1465-3249(05)70785-4 10.1016/S0301-472X(00)00617-2 10.1084/jem.188.9.1611 10.1038/ni1582 10.1016/S1471-4906(01)02060-9 10.1038/ni.2032 10.1016/S0959-8049(05)80028-0 10.1007/s10555-005-6192-2 10.4049/jimmunol.175.8.5095 10.1038/cmi.2011.47 10.1097/00002371-200001000-00018 10.3109/14653241003786155 10.4049/jimmunol.172.11.6598 10.1016/j.intimp.2012.09.014 10.1016/S1359-6101(01)00032-6 10.1182/blood-2008-06-165225 10.1002/ijc.2910160204 10.1016/j.trsl.2010.07.008 10.1080/14653240801965156 10.1182/blood-2003-12-4187 10.1038/cmi.2012.17 10.1038/cmi.2012.8 10.1016/j.exphem.2005.06.024 10.1111/j.1600-065X.2007.00563.x 10.2174/156800910791054167 10.2967/jnumed.109.061853 10.1007/BF01533386 10.1038/sj.bmt.1704086 10.1007/s00262-010-0878-1 10.1182/blood-2004-12-4797 10.3727/096368911X580536 10.1111/j.0105-2896.2004.00199.x 10.1007/s00262-007-0383-3 10.1016/S0169-5002(01)00292-6 10.1517/13543780903048911 10.1038/369031a0 10.4049/jimmunol.178.7.4011 10.4161/cbt.8.23.10455 10.1182/blood-2006-02-002055 10.4049/jimmunol.138.10.3566 10.4049/jimmunol.162.11.6658 10.1182/blood.V87.7.2632.bloodjournal8772632 10.1182/blood.V100.4.1265.h81602001265_1265_1273 10.4049/jimmunol.163.3.1473 10.4049/jimmunol.163.4.1906 10.1182/blood.V92.4.1374.416a33_1374_1383 10.1182/blood.V93.11.3876.411k25_3876_3884 10.1182/blood.V91.10.3850 10.1007/s00262-002-0336-9 10.4049/jimmunol.131.2.1024 10.1182/blood.V90.2.716 10.1182/blood.V92.11.4248 10.4049/jimmunol.134.6.4267 10.1182/blood.V93.5.1612 10.1182/blood.V83.9.2594.2594 |
| ContentType | Journal Article |
| Copyright | Chinese Society of Immunology and The University of Science and Technology 2013 Copyright Nature Publishing Group May 2013 Chinese Society of Immunology and The University of Science and Technology 2013. Copyright © 2013 Chinese Society of Immunology and The University of Science and Technology 2013 Chinese Society of Immunology and The University of Science and Technology |
| Copyright_xml | – notice: Chinese Society of Immunology and The University of Science and Technology 2013 – notice: Copyright Nature Publishing Group May 2013 – notice: Chinese Society of Immunology and The University of Science and Technology 2013. – notice: Copyright © 2013 Chinese Society of Immunology and The University of Science and Technology 2013 Chinese Society of Immunology and The University of Science and Technology |
| DBID | 2RA 92L CQIGP W91 ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 7T5 H94 5PM |
| DOI | 10.1038/cmi.2013.10 |
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Immunology Abstracts AIDS and Cancer Research Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts |
| DatabaseTitleList | ProQuest Central Student AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic ProQuest Central Student |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | NK cell-based immunotherapy for malignant diseases |
| EISSN | 2042-0226 |
| EndPage | 252 |
| ExternalDocumentID | PMC4076738 4040242341 23604045 10_1038_cmi_2013_10 46125738 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- -05 -0E -Q- -SE -S~ 0R~ 29B 2B. 2C~ 2RA 2WC 3V. 4.4 406 53G 5GY 5VR 6J9 70F 7X7 88E 8FE 8FH 8FI 8FJ 92F 92I 92L 92M 93N 93R 9D9 9DE AADWK AANZL AATNV AAWBL AAYFA AAYJO AAZLF ABAWZ ABGIJ ABJNI ABKZE ABUWG ACAOD ACBMV ACBRV ACBYP ACGFS ACIGE ACKTT ACPRK ACRQY ACTTH ACVWB ACZOJ ADFRT ADHDB ADMDM ADQMX ADYYL AEDAW AEFTE AEJRE AENEX AEVLU AEXYK AFKRA AFNRJ AFSHS AFUIB AGAYW AGEZK AGGBP AGHAI AHMBA AHSBF AILAN AJCLW AJDOV AJRNO ALMA_UNASSIGNED_HOLDINGS AMRJV AMYLF AXYYD BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CAJEE CAJUS CCEZO CCPQU CHBEP CIEJG CQIGP CW9 DIK DNIVK DPUIP DU5 EBLON EBS EE. EIOEI EJD F5P FA0 FDQFY FERAY FIZPM FRP FSGXE FYUFA GX1 HCIFZ HMCUK HYE HZ~ IWAJR JUIAU JZLTJ KQ8 LK8 M1P M7P NAO NQJWS NYICJ O9- OK1 P6G PQQKQ PROAC PSQYO Q-- Q-4 R-E RNT RNTTT RPM RT5 S.. SNX SNYQT SRMVM SWTZT T8U TAOOD TBHMF TCJ TDRGL TGQ TR2 TSG U1F U1G U5E U5O UKHRP W91 WFFXF ~88 ~MX ~WA AACDK AASML AAXDM ABAKF ABZZP AEFQL AEMSY AFBBN AGQEE AIGIU ALIPV FIGPU ROL AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC AEZWR AFDZB AFHIU AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT SOJ CGR CUY CVF ECM EIF NPM 7XB 8FK ABRTQ AZQEC DWQXO GNUQQ K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS PUEGO 7X8 7T5 H94 5PM |
| ID | FETCH-LOGICAL-c533t-2f5abec2eed93f37b752449d53532c13ae0fabd37ad9720f3df5c69e29cf14bc3 |
| IEDL.DBID | BENPR |
| ISSN | 1672-7681 2042-0226 |
| IngestDate | Thu Aug 21 13:55:07 EDT 2025 Fri Sep 05 04:42:41 EDT 2025 Fri Sep 05 09:53:14 EDT 2025 Sat Aug 23 14:49:56 EDT 2025 Fri Jul 25 09:10:21 EDT 2025 Thu Apr 03 06:56:48 EDT 2025 Thu Apr 24 23:09:21 EDT 2025 Tue Jul 01 01:08:40 EDT 2025 Fri Feb 21 02:37:11 EST 2025 Wed Feb 14 10:42:25 EST 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | clinical trial cancer natural killer cell immunotherapy expansion |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c533t-2f5abec2eed93f37b752449d53532c13ae0fabd37ad9720f3df5c69e29cf14bc3 |
| Notes | 11-4987/R Natural killer （NK） cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current NK cell-based cancer immunotherapy aims to overcome NK cell paralysis using several approaches. One approach uses expanded allogeneic NK cells, which are not inhibited by self histocompatibility antigens like autologous NK cells, for adoptive cellular immunotherapy. Another adoptive transfer approach uses stable allogeneic NK cell lines, which is more practical for quality control and large-scale production. A third approach is genetic modification of fresh NK cells or NK cell lines to highly express cytokines, Fc receptors and/or chimeric tumor-antigen receptors. Therapeutic NK cells can be derived from various sources, including peripheral or cord blood cells, stem cells or even induced pluripotent stem cells （iPSCs）, and a variety of stimulators can be used for large-scale production in laboratories or good manufacturing practice （GMP） facilities, including soluble growth factors, immobilized molecules or antibodies, and other cellular activators. A list of NK cell therapies to treat several types of cancer in clinical trials is reviewed here. Several different approaches to NK-based immunotherapy, such as tissue-specific NK cells, killer receptor-oriented NK cells and chemically treated NK cells, are discussed. A few new techniques or strategies to monitor NK cell therapy by non-invasive imaging, predetermine the efficiency of NK cell therapy by in vivo experiments and evaluate NK cell therapy approaches in clinical trials are also introduced. cancer; clinical trial; expansion; immunotherapy; natural killer cell ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | https://www.nature.com/articles/cmi201310.pdf |
| PMID | 23604045 |
| PQID | 1785511029 |
| PQPubID | 2041960 |
| PageCount | 23 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4076738 proquest_miscellaneous_1434036203 proquest_miscellaneous_1349092831 proquest_journals_2760385158 proquest_journals_1785511029 pubmed_primary_23604045 crossref_citationtrail_10_1038_cmi_2013_10 crossref_primary_10_1038_cmi_2013_10 springer_journals_10_1038_cmi_2013_10 chongqing_primary_46125738 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-05-01 |
| PublicationDateYYYYMMDD | 2013-05-01 |
| PublicationDate_xml | – month: 05 year: 2013 text: 2013-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: China |
| PublicationTitle | Cellular & molecular immunology |
| PublicationTitleAbbrev | Cell Mol Immunol |
| PublicationTitleAlternate | Cellular ＆ Molecular Immunology |
| PublicationYear | 2013 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Meller, Frohn, Brand, Lauer, Schelper, von Hof (CR191) 2004; 31 Cheng, Ma, Chen, Zhang, Zhao, Wei (CR127) 2011; 20 Yamane, Hank, Albertini, Sondel (CR121) 2009; 18 Tonn, Becker, Esser, Schwabe, Seifried (CR131) 2001; 10 Berg, Lundqvist, McCoy, Samsel, Fan, Tawab (CR164) 2009; 11 Paust, von Andrian (CR33) 2011; 12 Sutlu, Stellan, Gilljam, Quezada, Nahi, Gahrton (CR200) 2010; 12 Hayakawa, Smyth (CR38) 2006; 95 Kobayashi, Dubois, Sato, Sabzevari, Sakai, Waldmann (CR94) 2005; 105 Smyth, Kelly, Baxter, Korner, Sedgwick (CR51) 1998; 188 Nagashima, Mailliard, Kashii, Reichert, Herberman, Robbins (CR140) 1998; 91 Ruggeri, Mancusi, Burchielli, Capanni, Carotti, Aloisi (CR172) 2008; 40 Smyth, Thia, Cretney, Kelly, Snook, Forbes (CR52) 1999; 162 Ferlazzo, Munz (CR21) 2004; 172 Kohrt, Houot, Goldstein, Weiskopf, Alizadeh, Brody (CR120) 2011; 117 di Santo (CR17) 2006; 24 Keilholz, Scheibenbogen, Brado, Georgi, Maclachlan, Brado (CR91) 1994; 30A Smyth, Crowe, Pellicci, Kyparissoudis, Kelly, Takeda (CR62) 2002; 99 Colonna, Samaridis (CR29) 1995; 268 Villegas, Coca, Villarrubia, Jimenez, Chillon, Jareno (CR45) 2002; 35 Vitale, Sivori, Pende, Augugliaro, di Donato, Amoroso (CR25) 1996; 93 Costello, Sivori, Marcenaro, Lafage-Pochitaloff, Mozziconacci, Reviron (CR79) 2002; 99 Barlozzari, Reynolds, Herberman (CR37) 1983; 131 Becknell, Caligiuri (CR82) 2005; 86 Mocikat, Braumuller, Gumy, Egeter, Ziegler, Reusch (CR73) 2003; 19 Rizzieri, Storms, Chen, Long, Yang, Nikcevich (CR178) 2010; 16 Martin-Fontecha, Thomsen, Brett, Gerard, Lipp, Lanzavecchia (CR72) 2004; 5 Kaufman, Hanson, Lewis, Auerbach, Thomson (CR159) 2001; 98 Yagita, Huang, Umehara, Matsuo, Tabata, Miyake (CR130) 2000; 14 Arai, Klingemann (CR151) 2005; 5 Hernandez-Ilizaliturri, Reddy, Holkova, Ottman, Czuczman (CR123) 2005; 11 Salih, Rammensee, Steinle (CR8) 2002; 169 Anfossi, Andre, Guia, Falk, Roetynck, Stewart (CR20) 2006; 25 Miller (CR24) 2001; 29 Bradley, Zeytun, Rafi-Janajreh, Nagarkatti, Nagarkatti (CR55) 1998; 92 Sorkin, Otto, Baldwin, Vail, Gillies, Handgretinger (CR109) 2010; 149 Karre, Ljunggren, Piontek, Kiessling (CR48) 1986; 319 Yao, Sgadari, Furuke, Bloom, Teruya-Feldstein, Tosato (CR70) 1999; 93 Suck, Branch, Keating (CR135) 2006; 82 Cretney, Takeda, Yagita, Glaccum, Peschon, Smyth (CR59) 2002; 168 Tsuchiyama, Yoshino, Mori, Kondoh, Oka, Akagi (CR129) 1998; 92 Hayakawa, Hatano, Ogawa, Gakiya, Ogura, Osawa (CR88) 1994; 53 Kao, Yao, Kong, Wu, Chuang, Hwang (CR153) 2007; 16 Nguyen-Pham, Yang, Nguyen, Lim, Hong, Kim (CR75) 2012; 9 Shi, Ljunggren, la Cava, van Kaer (CR180) 2011; 11 Lapteva, Durett, Sun, Rollins, Huye, Fang (CR197) 2012; 14 Zhang, Sun, Wei, Tian (CR145) 2004; 11 Zamai, Ponti, Mirandola, Gobbi, Papa, Galeotti (CR95) 2007; 178 Zhang, Zhang, Niu, Tian (CR137) 2008; 42 Imai, Iwamoto, Campana (CR150) 2005; 106 Borghaei, Smith, Campbell (CR1) 2009; 625 Kodama, Takeda, Shimozato, Hayakawa, Atsuta, Kobayashi (CR68) 1999; 29 Ljunggren, Karre (CR47) 1985; 162 Parihar, Nadella, Lewis, Jensen, de Hoff, Dierksheide (CR114) 2004; 10 Slavin, Ackerstein, Or, Shapira, Gesundheit, Askenasy (CR173) 2010; 59 Sanchez-Correa, Morgado, Gayoso, Bergua, Casado, Arcos (CR182) 2011; 60 Geller, Cooley, Judson, Ghebre, Carson, Argenta (CR201) 2011; 13 Smyth, Cretney, Takeda, Wiltrout, Sedger, Kayagaki (CR69) 2001; 193 Trapani, Davis, Sutton, Smyth (CR54) 2000; 12 Konstantinidis, Alici, Aints, Christensson, Ljunggren, Dilber (CR144) 2005; 33 Kagi, Ledermann, Burki, Seiler, Odermatt, Olsen (CR53) 1994; 369 Patel, Kell, Simard, Xiang, Lin, Tian (CR195) 2011; 32 Street, Cretney, Smyth (CR61) 2001; 97 Betting, Yamada, Kafi, Said, van Rooijen, Timmerman (CR119) 2009; 32 Green, Bissonnette, Glynn, Shi (CR10) 1992; 4 Rodella, Zamai, Rezzani, Artico, Peri, Falconi (CR87) 2001; 115 Iliopoulou, Kountourakis, Karamouzis, Doufexis, Ardavanis, Baxevanis (CR104) 2010; 59 Yamaguchi, Sakaguchi (CR6) 2006; 16 Lundqvist, McCoy, Samsel, Childs (CR105) 2007; 109 Malmberg, Bryceson, Carlsten, Andersson, Bjorklund, Bjorkstrom (CR133) 2008; 57 Miller, Tessmer-Tuck, Pierson, Weisdorf, McGlave, Blazar (CR99) 1997; 3 Cerwenka, Lanier (CR23) 2001; 1 Sun, Lanier (CR34) 2011; 11 Mrozek, Anderson, Caligiuri (CR158) 1996; 87 Maki, Krystal, Dougherty, Takei, Klingemann (CR78) 1998; 12 Gong, Xiao, Hu, Weng, Qian, Pan (CR167) 2010; 76 Walzer, Dalod, Robbins, Zitvogel, Vivier (CR30) 2005; 106 Wu, Zhang, Zhang (CR32) 2011; 8 Condiotti, Zakai, Barak, Nagler (CR156) 2001; 29 Miller, Soignier, Panoskaltsis-Mortari, McNearney, Yun, Fautsch (CR103) 2005; 105 Saff, Spanjaard, Hohlbaum, Marshak-Rothstein (CR11) 2004; 172 Curti, Ruggeri, D'Addio, Bontadini, Dan, Motta (CR177) 2011; 118 Zagury, Gallo (CR4) 2004; 9 Schirrmann, Pecher (CR147) 2005; 29 Sola, Andre, Lemmers, Fuseri, Bonnafous, Blery (CR184) 2009; 106 Herberman, Holden (CR35) 1978; 27 Ljunggren, Karre (CR49) 1990; 11 Kim, Iizuka, Aguila, Weissman, Yokoyama (CR39) 2000; 97 Jiang, Zhang, Tian (CR142) 2008; 10 Kircher, Gambhir, Grimm (CR190) 2011; 8 Salih, Goehlsdorf, Steinle (CR7) 2006; 67 Geller, Cooley, Judson, Ghebre, Carson, Argenta (CR179) 2011; 13 Luevano, Madrigal, Saudemont (CR152) 2012; 9 Brady, Hayakawa, Smyth, Nutt (CR118) 2004; 172 Smyth, Hayakawa, Takeda, Yagita (CR40) 2002; 2 Schirrmann, Pecher (CR146) 2002; 9 Arai, Meagher, Swearingen, Myint, Rich, Martinson (CR171) 2008; 10 Purdy, Campbell (CR185) 2009; 8 Pedrinaci, Algarra, Garrido (CR139) 1999; 29 Cheng, Zhang, Jiang, Chen, Tian (CR126) 2012; 6 Coca, Perez-Piqueras, Martinez, Colmenarejo, Saez, Vallejo (CR43) 1997; 79 Ghiringhelli, Menard, Terme, Flament, Taieb, Chaput (CR86) 2005; 202 Spanholtz, Tordoir, Eissens, Preijers, van der Meer, Joosten (CR154) 2010; 5 Zhang, Sun, Wei, Tian (CR141) 2004; 89 Imai, Matsuyama, Miyake, Suga, Nakachi (CR42) 2000; 356 Tam, Maki, Miyagawa, Hennemann, Tonn, Klingemann (CR143) 1999; 10 van den Broek, Kagi, Zinkernagel, Hengartner (CR50) 1995; 25 Schultz, Klarnet, Peace, Cheever, Badger, Bernstein (CR116) 1990; 50 Screpanti, Wallin, Ljunggren, Grandien (CR56) 2001; 167 Herberman, Nunn, Lavrin (CR14) 1975; 16 Rosenberg, Lotze, Muul, Leitman, Chang, Ettinghausen (CR174) 1985; 313 Morse, Mosca, Clay, Lyerly (CR5) 2002; 2 Sutlu, Stellan, Gilljam, Quezada, Nahi, Gahrton (CR169) 2010; 12 Sutton, Henning, Pichler, Bremer, Daldrup-Link (CR193) 2008; 18 Gregoire, Chasson, Luci, Tomasello, Geissmann, Vivier (CR18) 2007; 220 Karlhofer, Ribaudo, Yokoyama (CR28) 1992; 358 Sconocchia, Titus, Segal (CR106) 1997; 90 Robertson, Cochran, Cameron, Le, Tantravahi, Ritz (CR136) 1996; 24 Talmadge, Phillips, Schindler, Tribble, Pennington (CR65) 1987; 47 Fujii, Trudeau, Teachey, Fish, Grupp, Schultz (CR187) 2007; 109 Kiessling, Klein, Wigzell (CR15) 1975; 5 Buhtoiarov, Neal, Gan, Buhtoiarova, Patankar, Gubbels (CR122) 2011; 89 Hayashi, Hideshima, Akiyama, Podar, Yasui, Raje (CR186) 2005; 128 Zalevsky, Leung, Karki, Chu, Zhukovsky, Desjarlais (CR112) 2009; 113 Siegler, Meyer-Monard, Jorger, Stern, Tichelli, Gratwohl (CR166) 2010; 12 Horton, Bernett, Pong, Peipp, Karki, Chu (CR111) 2008; 68 Bryceson, March, Ljunggren, Long (CR71) 2006; 214 Tam, Martinson, Doligosa, Klingemann (CR170) 2003; 5 Alderson, Sondel (CR108) 2011; 2011 Kayagaki, Yamaguchi, Nakayama, Takeda, Akiba, Tsutsui (CR57) 1999; 163 Colombo, Trinchieri (CR84) 2002; 13 Gerosa, Baldani-Guerra, Nisii, Marchesini, Carra, Trinchieri (CR77) 2002; 195 Farag, Caligiuri (CR80) 2004; 51 Voskens, Watanabe, Rollins, Campana, Hasumi, Mann (CR199) 2010; 29 Kaufman (CR160) 2009; 114 Velardi, Ruggeri, Mancusi, Aversa, Christiansen (CR125) 2009; 21 Kumar, McNerney (CR27) 2005; 5 Takeda, Hayakawa, Smyth, Kayagaki, Yamaguchi, Kakuta (CR58) 2001; 7 Subleski, Wiltrout, Weiss (CR181) 2009; 33 deMagalhaes-Silverman, Donnenberg, Lembersky, Elder, Lister, Rybka (CR98) 2000; 23 Kelly, Darcy, Markby, Godfrey, Takeda, Yagita (CR74) 2002; 3 Becker (CR2) 2006; 26 Ortaldo, Woodhouse, Morgan, Herberman, Cheresh, Reisfeld (CR115) 1987; 138 Jiang, Chen, Peng, Tian (CR16) 2012; 9 Iliopoulou, Kountourakis, Karamouzis, Doufexis, Ardavanis, Baxevanis (CR196) 2010; 59 Fujisaki, Kakuda, Shimasaki, Imai, Ma, Lockey (CR165) 2009; 69 Parkhurst, Riley, Dudley, Rosenberg (CR176) 2011; 17 Wu, Lanier (CR41) 2003; 90 Trinchieri (CR66) 1998; 70 Woll, Martin, Miller, Kaufman (CR162) 2005; 175 Romagne, Andre, Spee, Zahn, Anfossi, Gauthier (CR183) 2009; 114 Catchpole, Gould, Kellett-Gregory, Dobson (CR3) 2002; 43 Denman, Senyukov, Somanchi, Phatarpekar, Kopp, Johnson (CR168) 2012; 7 Woll, Grzywacz, Tian, Marcus, Knorr, Verneris (CR163) 2009; 113 Roder, Pross (CR22) 1982; 2 Pichler, Kolb, Nagele, Schlemmer (CR194) 2010; 51 Parihar, Dierksheide, Hu, Carson (CR113) 2002; 110 Vivier, Tomasello, Baratin, Walzer, Ugolini (CR26) 2008; 9 Tavri, Jha, Meier, Henning, Muller, Hostetter (CR192) 2009; 8 Binyamin, Alpaugh, Hughes, Lutz, Campbell, Weiner (CR124) 2008; 180 Waldhauer, Steinle (CR9) 2006; 66 Wiltrout, Herberman, Zhang, Chirigos, Ortaldo, Green (CR67) 1985; 134 Spanholtz, Preijers, Tordoir, Trilsbeek, Paardekooper, de Witte (CR155) 2011; 6 Sutlu, Alici (CR60) 2009; 266 Cooper, Fehniger, Caligiuri (CR19) 2001; 22 Uherek, Tonn, Uherek, Becker, Schnierle, Klingemann (CR148) 2002; 100 Cifone, D’Alo, Parroni, Millimaggi, Biordi, Martinotti (CR63) 1999; 93 Furuke, Burd, Horvath-Arcidiacono, Hori, Mostowski, Bloom (CR64) 1999; 163 Hayes, Koslow, Hiesiger, Hymes, Hochster, Moore (CR90) 1995; 76 CR83 Ruggeri, Mancusi, Perruccio, Burchielli, Martelli, Velardi (CR102) 2005; 28 Yoneda, Tatsumi, Kawano, Teshigawara, Oka, Fukuda (CR128) 1992; 6 Baxevanis, Perez, Papamichail (CR12) 2009; 46 Zhao, Xu, Wang, Kryczek, Wu, Hu (CR13) 2012; 9 Navid, Santana, Barfield (CR110) 2010; 10 Miller, Alley, McGlave (CR157) 1994; 83 Riccardi, Santoni, Barlozzari, Puccetti, Herberman (CR36) 1980; 25 Ljunggren, Malmberg (CR46) 2007; 7 Klingemann (CR132) 2005; 7 Krause, Gastpar, Andreesen, Gross, Ullrich, Thonigs (CR175) 2004; 10 Jha, Golovko, Bains, Hostetter, Meier, Wendland (CR189) 2010; 70 Berzofsky, Ahlers, Belyakov (CR93) 2001; 1 Ruggeri, Capanni, Urbani, Perruccio, Shlomchik, Tosti (CR101) 2002; 295 Knorr, Kaufman (CR161) 2010; 156 Waldhauer, Steinle (CR31) 2008; 27 Brandau, Ri F Romagne (BFcmi201310_CR183) 2009; 114 MJ Smyth (BFcmi201310_CR62) 2002; 99 E Ishikawa (BFcmi201310_CR97) 2004; 24 SS Farag (BFcmi201310_CR80) 2004; 51 J Brady (BFcmi201310_CR118) 2004; 172 HR Salih (BFcmi201310_CR7) 2006; 67 D Piccioli (BFcmi201310_CR76) 2002; 195 D Kagi (BFcmi201310_CR53) 1994; 369 A Lundqvist (BFcmi201310_CR105) 2007; 109 Y Becker (BFcmi201310_CR2) 2006; 26 MR Parkhurst (BFcmi201310_CR176) 2011; 17 JA Trapani (BFcmi201310_CR54) 2000; 12 M Cheng (BFcmi201310_CR126) 2012; 6 L Ruggeri (BFcmi201310_CR172) 2008; 40 S Tavri (BFcmi201310_CR192) 2009; 8 T Schirrmann (BFcmi201310_CR147) 2005; 29 C Gregoire (BFcmi201310_CR18) 2007; 220 CN Baxevanis (BFcmi201310_CR12) 2009; 46 M Bradley (BFcmi201310_CR55) 1998; 92 M Berg (BFcmi201310_CR164) 2009; 11 YK Tam (BFcmi201310_CR170) 2003; 5 EJ Sutton (BFcmi201310_CR193) 2008; 18 E Cretney (BFcmi201310_CR59) 2002; 168 B Escudier (BFcmi201310_CR96) 1994; 30A SW Krause (BFcmi201310_CR175) 2004; 10 X Deng (BFcmi201310_CR198) 2012; 14 YT Bryceson (BFcmi201310_CR71) 2006; 214 HG Ljunggren (BFcmi201310_CR46) 2007; 7 J Spanholtz (BFcmi201310_CR154) 2010; 5 T Yamaguchi (BFcmi201310_CR6) 2006; 16 U Siegler (BFcmi201310_CR166) 2010; 12 MG Cifone (BFcmi201310_CR63) 1999; 93 F Ghiringhelli (BFcmi201310_CR86) 2005; 202 YK Tam (BFcmi201310_CR143) 1999; 10 S Pedrinaci (BFcmi201310_CR139) 1999; 29 DA Rizzieri (BFcmi201310_CR178) 2010; 16 RR Saff (BFcmi201310_CR11) 2004; 172 MF Kircher (BFcmi201310_CR190) 2011; 8 SA Rosenberg (BFcmi201310_CR85) 1984; 3 G Maki (BFcmi201310_CR78) 1998; 12 M Luevano (BFcmi201310_CR152) 2012; 9 D Patel (BFcmi201310_CR195) 2011; 32 J Zhang (BFcmi201310_CR145) 2004; 11 H Fujii (BFcmi201310_CR187) 2007; 109 T Muller (BFcmi201310_CR149) 2008; 57 A Curti (BFcmi201310_CR177) 2011; 118 MA Cooper (BFcmi201310_CR19) 2001; 22 K Takeda (BFcmi201310_CR58) 2001; 7 F Gerosa (BFcmi201310_CR77) 2002; 195 MJ Smyth (BFcmi201310_CR52) 1999; 162 RT Costello (BFcmi201310_CR79) 2002; 99 HG Ljunggren (BFcmi201310_CR47) 1985; 162 EG Iliopoulou (BFcmi201310_CR196) 2010; 59 T Kodama (BFcmi201310_CR68) 1999; 29 J Tsuchiyama (BFcmi201310_CR129) 1998; 92 RB Herberman (BFcmi201310_CR35) 1978; 27 K Furuke (BFcmi201310_CR64) 1999; 163 KR Schultz (BFcmi201310_CR116) 1990; 50 M Yagita (BFcmi201310_CR130) 2000; 14 DS Kaufman (BFcmi201310_CR160) 2009; 114 M deMagalhaes-Silverman (BFcmi201310_CR98) 2000; 23 L Yao (BFcmi201310_CR70) 1999; 93 HR Salih (BFcmi201310_CR8) 2002; 169 E Vivier (BFcmi201310_CR26) 2008; 9 T Sutlu (BFcmi201310_CR60) 2009; 266 S Arai (BFcmi201310_CR151) 2005; 5 DR Green (BFcmi201310_CR10) 1992; 4 JR Ortaldo (BFcmi201310_CR115) 1987; 138 C Sola (BFcmi201310_CR184) 2009; 106 BH Yamane (BFcmi201310_CR121) 2009; 18 M Cheng (BFcmi201310_CR127) 2011; 20 BJ Pichler (BFcmi201310_CR194) 2010; 51 N Kayagaki (BFcmi201310_CR57) 1999; 163 I Waldhauer (BFcmi201310_CR9) 2006; 66 JS Miller (BFcmi201310_CR103) 2005; 105 MA Geller (BFcmi201310_CR179) 2011; 13 B Catchpole (BFcmi201310_CR3) 2002; 43 C Riccardi (BFcmi201310_CR36) 1980; 25 S Kim (BFcmi201310_CR39) 2000; 97 JM Kelly (BFcmi201310_CR74) 2002; 3 G Ferlazzo (BFcmi201310_CR21) 2004; 172 L Ruggeri (BFcmi201310_CR101) 2002; 295 C Imai (BFcmi201310_CR150) 2005; 106 B Becknell (BFcmi201310_CR82) 2005; 86 MP Colombo (BFcmi201310_CR84) 2002; 13 PS Woll (BFcmi201310_CR162) 2005; 175 HE Kohrt (BFcmi201310_CR120) 2011; 117 U Keilholz (BFcmi201310_CR91) 1994; 30A JC Sun (BFcmi201310_CR34) 2011; 11 E Zhao (BFcmi201310_CR13) 2012; 9 L Zamai (BFcmi201310_CR95) 2007; 178 G Trinchieri (BFcmi201310_CR66) 1998; 70 J Zhang (BFcmi201310_CR141) 2004; 89 N Lapteva (BFcmi201310_CR197) 2012; 14 S Slavin (BFcmi201310_CR173) 2010; 59 A Cerwenka (BFcmi201310_CR23) 2001; 1 E Mrozek (BFcmi201310_CR158) 1996; 87 MF van den Broek (BFcmi201310_CR50) 1995; 25 AK Purdy (BFcmi201310_CR185) 2009; 8 L Wu (BFcmi201310_CR32) 2011; 8 S Arai (BFcmi201310_CR171) 2008; 10 LJ Burns (BFcmi201310_CR100) 2003; 32 TN Nguyen-Pham (BFcmi201310_CR75) 2012; 9 A Boiardi (BFcmi201310_CR89) 1994; 39 J Spanholtz (BFcmi201310_CR155) 2011; 6 L Rodella (BFcmi201310_CR87) 2001; 115 HL Ma (BFcmi201310_CR92) 2003; 171 JS Miller (BFcmi201310_CR24) 2001; 29 C Zhang (BFcmi201310_CR137) 2008; 42 BFcmi201310_CR83 H Fujisaki (BFcmi201310_CR165) 2009; 69 A Velardi (BFcmi201310_CR125) 2009; 21 JS Miller (BFcmi201310_CR99) 1997; 3 SA Rosenberg (BFcmi201310_CR174) 1985; 313 B Meller (BFcmi201310_CR191) 2004; 31 M Colonna (BFcmi201310_CR29) 1995; 268 SE Street (BFcmi201310_CR61) 2001; 97 RL Hayes (BFcmi201310_CR90) 1995; 76 DA Knorr (BFcmi201310_CR161) 2010; 156 V Kumar (BFcmi201310_CR27) 2005; 5 MJ Smyth (BFcmi201310_CR81) 2004; 202 T Tonn (BFcmi201310_CR131) 2001; 10 J Zalevsky (BFcmi201310_CR112) 2009; 113 T Walzer (BFcmi201310_CR30) 2005; 106 B Sanchez-Correa (BFcmi201310_CR182) 2011; 60 HG Ljunggren (BFcmi201310_CR49) 1990; 11 CJ Voskens (BFcmi201310_CR199) 2010; 29 R Parihar (BFcmi201310_CR114) 2004; 10 Y Hayakawa (BFcmi201310_CR38) 2006; 95 IN Buhtoiarov (BFcmi201310_CR122) 2011; 89 PS Woll (BFcmi201310_CR163) 2009; 113 T Schirrmann (BFcmi201310_CR146) 2002; 9 X Jiang (BFcmi201310_CR16) 2012; 9 FM Karlhofer (BFcmi201310_CR28) 1992; 358 IT Kao (BFcmi201310_CR153) 2007; 16 T Hayashi (BFcmi201310_CR186) 2005; 128 FR Villegas (BFcmi201310_CR45) 2002; 35 KV Konstantinidis (BFcmi201310_CR144) 2005; 33 M Hayakawa (BFcmi201310_CR88) 1994; 53 MJ Smyth (BFcmi201310_CR40) 2002; 2 R Condiotti (BFcmi201310_CR156) 2001; 29 MA Geller (BFcmi201310_CR201) 2011; 13 T Barlozzari (BFcmi201310_CR37) 1983; 131 MJ Smyth (BFcmi201310_CR69) 2001; 193 JC Roder (BFcmi201310_CR22) 1982; 2 R Parihar (BFcmi201310_CR113) 2002; 110 L Binyamin (BFcmi201310_CR124) 2008; 180 Silke Paust (BFcmi201310_CR33) 2011; 12 F Navid (BFcmi201310_CR110) 2010; 10 S Ishigami (BFcmi201310_CR44) 2000; 88 S Nagashima (BFcmi201310_CR140) 1998; 91 EG Iliopoulou (BFcmi201310_CR104) 2010; 59 FD Shi (BFcmi201310_CR180) 2011; 11 LS Sorkin (BFcmi201310_CR109) 2010; 149 S Brandau (BFcmi201310_CR188) 2001; 92 G Sconocchia (BFcmi201310_CR106) 1997; 90 CJ Denman (BFcmi201310_CR168) 2012; 7 MJ Robertson (BFcmi201310_CR136) 1996; 24 RH Wiltrout (BFcmi201310_CR67) 1985; 134 L Ruggeri (BFcmi201310_CR102) 2005; 28 RB Herberman (BFcmi201310_CR14) 1975; 16 T Sutlu (BFcmi201310_CR200) 2010; 12 JJ Subleski (BFcmi201310_CR181) 2009; 33 A Martin-Fontecha (BFcmi201310_CR72) 2004; 5 KL Alderson (BFcmi201310_CR108) 2011; 2011 MA Morse (BFcmi201310_CR5) 2002; 2 V Screpanti (BFcmi201310_CR56) 2001; 167 HG Klingemann (BFcmi201310_CR132) 2005; 7 G Suck (BFcmi201310_CR135) 2006; 82 H Borghaei (BFcmi201310_CR1) 2009; 625 N Anfossi (BFcmi201310_CR20) 2006; 25 N Yoneda (BFcmi201310_CR128) 1992; 6 I Waldhauer (BFcmi201310_CR31) 2008; 27 J Wu (BFcmi201310_CR41) 2003; 90 C Uherek (BFcmi201310_CR148) 2002; 100 P Jha (BFcmi201310_CR189) 2010; 70 S Coca (BFcmi201310_CR43) 1997; 79 M Vitale (BFcmi201310_CR25) 1996; 93 DS Kaufman (BFcmi201310_CR159) 2001; 98 A Garcia-Lora (BFcmi201310_CR138) 2003; 52 JS Miller (BFcmi201310_CR157) 1994; 83 K Karre (BFcmi201310_CR48) 1986; 319 DJ Betting (BFcmi201310_CR119) 2009; 32 W Gong (BFcmi201310_CR167) 2010; 76 T Sutlu (BFcmi201310_CR169) 2010; 12 J Parrish-Novak (BFcmi201310_CR117) 2000; 408 A Iannello (BFcmi201310_CR107) 2005; 24 HM Horton (BFcmi201310_CR111) 2008; 68 G Suck (BFcmi201310_CR134) 2005; 33 R Kiessling (BFcmi201310_CR15) 1975; 5 W Jiang (BFcmi201310_CR142) 2008; 10 JE Talmadge (BFcmi201310_CR65) 1987; 47 JA Berzofsky (BFcmi201310_CR93) 2001; 1 R Mocikat (BFcmi201310_CR73) 2003; 19 H Kobayashi (BFcmi201310_CR94) 2005; 105 FJ Hernandez-Ilizaliturri (BFcmi201310_CR123) 2005; 11 KJ Malmberg (BFcmi201310_CR133) 2008; 57 JP di Santo (BFcmi201310_CR17) 2006; 24 K Imai (BFcmi201310_CR42) 2000; 356 D Zagury (BFcmi201310_CR4) 2004; 9 MJ Smyth (BFcmi201310_CR51) 1998; 188 7654433 - Eur J Cancer. 1994;30A(8):1078-83 19652198 - Blood. 2009 Oct 22;114(17):3513-23 10803526 - Leukemia. 2000 May;14(5):922-30 11900991 - Cytokine Growth Factor Rev. 2002 Apr;13(2):155-68 15297404 - Clin Cancer Res. 2004 Aug 1;10(15):5027-37 23063974 - Int Immunopharmacol. 2012 Dec;14(4):593-605 11960290 - Cancer Gene Ther. 2002 Apr;9(4):390-8 11117911 - Lancet. 2000 Nov 25;356(9244):1795-9 15153474 - J Immunol. 2004 Jun 1;172(11):6598-606 17964828 - Blood Cells Mol Dis. 2008 Jan-Feb;40(1):84-90 14685783 - Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):403-7 19717293 - Curr Opin Immunol. 2009 Oct;21(5):525-30 19308771 - Cytotherapy. 2009;11(3):341-55 2437198 - J Immunol. 1987 May 15;138(10):3566-72 10365666 - Hum Gene Ther. 1999 May 20;10(8):1359-73 6292259 - J Clin Immunol. 1982 Oct;2(4):249-63 11535826 - Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10716-21 2386946 - Cancer Res. 1990 Sep 1;50(17):5421-5 15755898 - Blood. 2005 Jul 1;106(1):376-83 11340575 - Int J Cancer. 2001 Jun 1;92(5):697-702 21669033 - Cell Transplant. 2011;20(11-12):1731-46 6389777 - J Biol Response Mod. 1984 Oct;3(5):501-11 18425107 - Nat Immunol. 2008 May;9(5):503-10 19561305 - Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84 8566046 - Eur J Immunol. 1995 Dec;25(12):3514-6 10685650 - Cancer J Sci Am. 2000 Feb;6 Suppl 1:S2-7 19553639 - Blood. 2009 Sep 24;114(13):2667-77 12536241 - Cancer Immunol Immunother. 2003 Jan;52(1):59-64 11905830 - Nat Rev Immunol. 2001 Dec;1(3):209-19 50294 - Int J Cancer. 1975 Aug 15;16(2):216-29 21739673 - Nat Immunol. 2011 Jun;12(6):500-8 12847225 - J Immunol. 2003 Jul 15;171(2):608-15 17979846 - Immunol Rev. 2007 Dec;220:169-82 18836917 - Cytotherapy. 2008;10(6):625-32 11135622 - Nat Med. 2001 Jan;7(1):94-100 15464915 - Adv Pharmacol. 2004;51:295-318 2201309 - Immunol Today. 1990 Jul;11(7):237-44 20937115 - J Exp Clin Cancer Res. 2010;29:134 22460449 - Front Med. 2012 Mar;6(1):56-66 7513206 - Blood. 1994 May 1;83(9):2594-601 3989307 - J Immunol. 1985 Jun;134(6):4267-75 22279576 - PLoS One. 2012;7(1):e30264 17179231 - Blood. 2007 Apr 15;109(8):3603-6 11522236 - J Hematother Stem Cell Res. 2001 Aug;10(4):535-44 9226172 - Blood. 1997 Jul 15;90(2):716-25 12370276 - J Clin Invest. 2002 Oct;110(7):983-92 8142149 - Eur J Cancer. 1994;30A(1):103-5 21822297 - Cell Mol Immunol. 2012 Jan;9(1):45-53 17999637 - Stem Cells Dev. 2007 Dec;16(6):1043-51 3903508 - N Engl J Med. 1985 Dec 5;313(23):1485-92 12149207 - Blood. 2002 Aug 15;100(4):1265-73 15676209 - Exp Hematol. 2005 Feb;33(2):159-64 7716543 - Science. 1995 Apr 21;268(5209):405-8 11828007 - J Exp Med. 2002 Feb 4;195(3):327-33 22504953 - Cell Mol Immunol. 2012 May;9(3):193-4 10415049 - J Immunol. 1999 Aug 1;163(3):1473-80 16115943 - Clin Cancer Res. 2005 Aug 15;11(16):5984-92 18317755 - Cancer Immunol Immunother. 2008 Oct;57(10):1541-52 21946842 - Nat Rev Clin Oncol. 2011 Nov;8(11):677-88 15069553 - Oncol Rep. 2004 May;11(5):1097-106 18506449 - Eur Radiol. 2008 Oct;18(10):2021-32 17717662 - Cancer Immunol Immunother. 2008 Mar;57(3):411-23 21644031 - Cancer Immunol Immunother. 2011 Aug;60(8):1195-205 9755338 - Adv Immunol. 1998;70:83-243 18829563 - Cancer Res. 2008 Oct 1;68(19):8049-57 15012931 - Drug Discov Today. 2004 Jan 15;9(2):72-81 14764669 - J Immunol. 2004 Feb 15;172(4):2048-58 8164737 - Nature. 1994 May 5;369(6475):31-7 16230475 - J Exp Med. 2005 Oct 17;202(8):1075-85 11750709 - Lung Cancer. 2002 Jan;35(1):23-8 16510567 - Cancer Res. 2006 Mar 1;66(5):2520-6 19650714 - Crit Rev Clin Lab Sci. 2009;46(4):167-89 10438925 - J Immunol. 1999 Aug 15;163(4):1906-13 21660134 - J Biomed Biotechnol. 2011;2011:379123 19548853 - Expert Opin Investig Drugs. 2009 Jul;18(7):991-1000 17371953 - J Immunol. 2007 Apr 1;178(7):4011-6 16901727 - Immunity. 2006 Aug;25(2):331-42 11133760 - Blood. 2001 Jan 1;97(1):192-7 19483647 - J Immunother. 2009 Jul-Aug;32(6):622-31 11703348 - Br J Haematol. 2001 Nov;115(2):442-50 22020068 - Cell Mol Immunol. 2012 Jan;9(1):11-9 20563804 - Cancer Immunol Immunother. 2010 Oct;59(10):1511-9 19682859 - J Autoimmun. 2009 Nov-Dec;33(3-4):275-81 3499218 - Cancer Res. 1987 Nov 1;47(21):5725-32 19614820 - J Intern Med. 2009 Aug;266(2):154-81 17068155 - Blood. 2007 Mar 1;109(5):2008-13 11081504 - Nature. 2000 Nov 2;408(6808):57-63 1313126 - Leukemia. 1992 Feb;6(2):136-41 14710949 - Adv Cancer Res. 2003;90:127-56 15274367 - Anticancer Res. 2004 May-Jun;24(3b):1861-71 10694580 - Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2731-6 11164111 - Exp Hematol. 2001 Jan;29(1):104-13 12850795 - Cytotherapy. 2003;5(3):259-72 10339496 - Blood. 1999 Jun 1;93(11):3876-84 21193697 - Blood. 2011 Feb 24;117(8):2423-32 19344572 - Mol Imaging. 2009 Jan-Feb;8(1):15-26 19365083 - Blood. 2009 Jun 11;113(24):6094-101 9834230 - Blood. 1998 Dec 1;92(11):4248-55 12838283 - Bone Marrow Transplant. 2003 Jul;32(2):177-86 15705423 - Adv Immunol. 2005;86:209-39 16376102 - Semin Cancer Biol. 2006 Apr;16(2):115-23 14563320 - Immunity. 2003 Oct;19(4):561-9 8599969 - Exp Hematol. 1996 Feb;24(3):406-15 11801676 - J Immunol. 2002 Feb 1;168(3):1356-61 22705914 - Cell Mol Immunol. 2012 Jul;9(4):310-20 9573023 - Blood. 1998 May 15;91(10):3850-61 18418772 - Cytotherapy. 2008;10(3):265-74 21698239 - PLoS One. 2011;6(6):e20740 16040380 - Cytotherapy. 2005;7(1):16-22 18280748 - Cytokine. 2008 Apr;42(1):128-36 8643653 - Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1453-7 15638853 - Br J Haematol. 2005 Jan;128(2):192-203 15020274 - Haematologica. 2004 Mar;89(3):338-47 11257133 - J Exp Med. 2001 Mar 19;193(6):661-70 11905813 - Nat Rev Immunol. 2001 Oct;1(1):41-9 18424763 - J Immunol. 2008 May 1;180(9):6392-401 20491532 - Cytotherapy. 2010 Oct;12(6):750-63 1286165 - Semin Immunol. 1992 Dec;4(6):379-88 9191519 - Cancer. 1997 Jun 15;79(12):2320-8 11743585 - Nat Immunol. 2002 Jan;3(1):83-90 10229107 - Eur J Immunol. 1999 Apr;29(4):1390-6 21035183 - Biomaterials. 2011 Feb;32(4):1167-76 20201786 - Curr Cancer Drug Targets. 2010 Mar;10(2):200-9 9802973 - J Exp Med. 1998 Nov 2;188(9):1611-9 12370336 - J Immunol. 2002 Oct 15;169(8):4098-102 21941294 - Nat Rev Immunol. 2011 Oct;11(10):658-71 11896281 - Science. 2002 Mar 15;295(5562):2097-100 3877776 - J Exp Med. 1985 Dec 1;162(6):1745-59 20188202 - Biol Blood Marrow Transplant. 2010 Aug;16(8):1107-14 19923897 - Cancer Biol Ther. 2009 Dec;8(23):2211-20 12415255 - Nat Rev Cancer. 2002 Nov;2(11):850-61 20631071 - Cancer Res. 2010 Aug 1;70(15):6109-13 10649250 - Cancer. 2000 Feb 1;88(3):577-83 15757378 - Expert Opin Biol Ther. 2005 Feb;5(2):163-72 21248148 - J Leukoc Biol. 2011 Apr;89(4):625-38 3951539 - Nature. 1986 Feb 20-26;319(6055):675-8 10687148 - J Immunother. 2000 Jan;23(1):154-60 15933055 - Blood. 2005 Oct 1;106(7):2252-8 20171010 - Pain. 2010 Apr;149(1):135-42 15632206 - Blood. 2005 Apr 15;105(8):3051-7 8639878 - Blood. 1996 Apr 1;87(7):2632-40 20801411 - Transl Res. 2010 Sep;156(3):147-54 6154658 - Int J Cancer. 1980 Apr 15;25(4):475-86 16619514 - Anticancer Res. 2006 Mar-Apr;26(2A):1113-34 19109559 - Blood. 2009 Apr 16;113(16):3735-43 15841099 - Nat Rev Immunol. 2005 May;5(5):363-74 7923250 - Cancer Immunol Immunother. 1994 Sep;39(3):193-7 21844012 - Clin Cancer Res. 2011 Oct 1;17(19):6287-97 15531883 - Nat Immunol. 2004 Dec;5(12):1260-5 11830474 - Blood. 2002 Feb 15;99(4):1259-66 9766501 - Leukemia. 1998 Oct;12(10):1565-72 16551250 - Annu Rev Immunol. 2006;24:257-86 11602317 - Exp Hematol. 2001 Oct;29(10):1157-68 11698225 - Trends Immunol. 2001 Nov;22(11):633-40 6863925 - J Immunol. 1983 Aug;131(2):1024-7 22900959 - Cytotherapy. 2012 Oct;14(9):1131-43 11489989 - J Immunol. 2001 Aug 15;167(4):2068-73 11772338 - Expert Opin Biol Ther. 2002 Jan;2(1):35-43 20849361 - Cytotherapy. 2011 Jan;13(1):98-107 21706044 - Cell Mol Immunol. 2011 Sep;8(5):433-40 20795758 - Cytotherapy. 2010 Dec;12(8):1044-55 10781403 - Curr Opin Immunol. 2000 Jun;12(3):323-9 15173076 - Clin Cancer Res. 2004 Jun 1;10(11):3699-707 16408158 - Cancer Metastasis Rev. 2005 Dec;24(4):487-99 16210613 - J Immunol. 2005 Oct 15;175(8):5095-103 20703455 - Cancer Immunol Immunother. 2010 Dec;59(12):1781-9 9209739 - Biol Blood Marrow Transplant. 1997 Apr;3(1):34-44 21869816 - Nat Rev Immunol. 2011 Oct;11(10):645-57 11986221 - Blood. 2002 May 15;99(10):3661-7 11828008 - J Exp Med. 2002 Feb 4;195(3):335-41 9694726 - Blood. 1998 Aug 15;92(4):1374-83 16219538 - Exp Hematol. 2005 Oct;33(10):1160-71 8625188 - Cancer. 1995 Sep 1;76(5):840-52 20150252 - J Nucl Med. 2010 Mar;51(3):333-6 14734707 - J Immunol. 2004 Feb 1;172(3):1333-9 1614533 - Nature. 1992 Jul 2;358(6381):66-70 15367431 - Blood. 2005 Jan 15;105(2):721-7 10352283 - J Immunol. 1999 Jun 1;162(11):6658-62 16782653 - Int J Radiat Biol. 2006 May;82(5):355-61 7645136 - Urol Int. 1994;53(3):117-24 17438573 - Nat Rev Immunol. 2007 May;7(5):329-39 15838373 - J Immunother. 2005 May-Jun;28(3):175-82 16698441 - Hum Immunol. 2006 Mar;67(3):188-95 21791425 - Blood. 2011 Sep 22;118(12):3273-9 356546 - Adv Cancer Res. 1978;27:305-77 19837059 - Eur J Pharmacol. 2009 Dec 25;625(1-3):41-54 20670353 - Tissue Antigens. 2010 Dec;76(6):467-75 12400646 - J Small Anim Pract. 2002 Oct;43(10):464-7 19383914 - Cancer Res. 2009 May 1;69(9):4010-7 17100877 - Immunol Rev. 2006 Dec;214:73-91 20169160 - PLoS One. 2010;5(2):e9221 15546400 - Immunol Rev. 2004 Dec;202:275-93 15661266 - Leuk Res. 2005 Mar;29(3):301-6 10029590 - Blood. 1999 Mar 1;93(5):1612-21 1234049 - Eur J Immunol. 1975 Feb;5(2):112-7 16860661 - Adv Cancer Res. 2006;95:293-322 10784373 - Int J Clin Lab Res. 1999;29(4):135-40 18836474 - Oncogene. 2008 Oct 6;27(45):5932-43 |
| References_xml | – volume: 83 start-page: 2594 year: 1994 end-page: 2601 ident: CR157 article-title: Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34 7 NK progenitor publication-title: Blood – volume: 95 start-page: 293 year: 2006 end-page: 322 ident: CR38 article-title: Innate immune recognition and suppression of tumors publication-title: Adv Cancer Res doi: 10.1016/S0065-230X(06)95008-8 – volume: 50 start-page: 5421 year: 1990 end-page: 5425 ident: CR116 article-title: Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells publication-title: Cancer Res – volume: 30A start-page: 1078 year: 1994 end-page: 1083 ident: CR96 article-title: Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2 publication-title: Eur J Cancer A doi: 10.1016/0959-8049(94)90460-X – volume: 25 start-page: 331 year: 2006 end-page: 342 ident: CR20 article-title: Human NK cell education by inhibitory receptors for MHC class I publication-title: Immunity doi: 10.1016/j.immuni.2006.06.013 – volume: 163 start-page: 1473 year: 1999 end-page: 1480 ident: CR64 article-title: Human NK cells express endothelial nitric oxide synthase, and nitric oxide protects them from activation-induced cell death by regulating expression of TNF-alpha publication-title: J Immunol – volume: 14 start-page: 922 year: 2000 end-page: 930 ident: CR130 article-title: A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation publication-title: Leukemia doi: 10.1038/sj.leu.2401769 – volume: 162 start-page: 6658 year: 1999 end-page: 6662 ident: CR52 article-title: Perforin is a major contributor to NK cell control of tumor metastasis publication-title: J Immunol – volume: 92 start-page: 1374 year: 1998 end-page: 1383 ident: CR129 article-title: Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection publication-title: Blood – volume: 31 start-page: 403 year: 2004 end-page: 407 ident: CR191 article-title: Monitoring of a new approach of immunotherapy with allogenic (111)In-labelled NK cells in patients with renal cell carcinoma publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-003-1398-4 – volume: 12 start-page: 1044 year: 2010 end-page: 1055 ident: CR169 article-title: Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor publication-title: Cytotherapy doi: 10.3109/14653249.2010.504770 – volume: 11 start-page: 237 year: 1990 end-page: 244 ident: CR49 article-title: In search of the ‘missing self’: MHC molecules and NK cell recognition publication-title: Immunol Today doi: 10.1016/0167-5699(90)90097-S – volume: 202 start-page: 1075 year: 2005 end-page: 1085 ident: CR86 article-title: CD4 CD25 regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner publication-title: J Exp Med doi: 10.1084/jem.20051511 – volume: 115 start-page: 442 year: 2001 end-page: 450 ident: CR87 article-title: Interleukin 2 and interleukin 15 differentially predispose natural killer cells to apoptosis mediated by endothelial and tumour cells publication-title: Br J Haematol doi: 10.1046/j.1365-2141.2001.03055.x – volume: 93 start-page: 3876 year: 1999 end-page: 3884 ident: CR63 article-title: Interleukin-2-activated rat natural killer cells express inducible nitric oxide synthase that contributes to cytotoxic function and interferon-gamma production publication-title: Blood – volume: 8 start-page: 15 year: 2009 end-page: 26 ident: CR192 article-title: Optical imaging of cellular immunotherapy against prostate cancer publication-title: Mol Imaging doi: 10.2310/7290.2009.00002 – volume: 24 start-page: 1861 year: 2004 end-page: 1871 ident: CR97 article-title: Autologous natural killer cell therapy for human recurrent malignant glioma publication-title: Anticancer Res – volume: 162 start-page: 1745 year: 1985 end-page: 1759 ident: CR47 article-title: Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism publication-title: J Exp Med doi: 10.1084/jem.162.6.1745 – volume: 10 start-page: 5027 year: 2004 end-page: 5037 ident: CR114 article-title: A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-0265 – volume: 86 start-page: 209 year: 2005 end-page: 239 ident: CR82 article-title: Interleukin-2, interleukin-15, and their roles in human natural killer cells publication-title: Adv Immunol doi: 10.1016/S0065-2776(04)86006-1 – volume: 1 start-page: 209 year: 2001 end-page: 219 ident: CR93 article-title: Strategies for designing and optimizing new generation vaccines publication-title: Nat Rev Immunol doi: 10.1038/35105075 – volume: 195 start-page: 335 year: 2002 end-page: 341 ident: CR76 article-title: Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells publication-title: J Exp Med doi: 10.1084/jem.20010934 – volume: 70 start-page: 83 year: 1998 end-page: 243 ident: CR66 article-title: Interleukin-12: a cytokine at the interface of inflammation and immunity publication-title: Adv Immunol doi: 10.1016/S0065-2776(08)60387-9 – volume: 43 start-page: 464 year: 2002 end-page: 467 ident: CR3 article-title: Immunosuppressive cytokines in the regional lymph node of a dog suffering from oral malignant melanoma publication-title: J Small Anim Pract doi: 10.1111/j.1748-5827.2002.tb00015.x – volume: 10 start-page: 625 year: 2008 end-page: 632 ident: CR171 article-title: Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial publication-title: Cytotherapy doi: 10.1080/14653240802301872 – volume: 3 start-page: 83 year: 2002 end-page: 90 ident: CR74 article-title: Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection publication-title: Nat Immunol doi: 10.1038/ni746 – volume: 98 start-page: 10716 year: 2001 end-page: 10721 ident: CR159 article-title: Hematopoietic colony-forming cells derived from human embryonic stem cells publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.191362598 – volume: 9 start-page: 45 year: 2012 end-page: 53 ident: CR75 article-title: Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy publication-title: Cell Mol Immunol doi: 10.1038/cmi.2011.23 – volume: 69 start-page: 4010 year: 2009 end-page: 4017 ident: CR165 article-title: Expansion of highly cytotoxic human natural killer cells for cancer cell therapy publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-3712 – volume: 32 start-page: 1167 year: 2011 end-page: 1176 ident: CR195 article-title: The cell labeling efficacy, cytotoxicity and relaxivity of copper-activated MRI/PET imaging contrast agents publication-title: Biomaterials doi: 10.1016/j.biomaterials.2010.10.013 – volume: 25 start-page: 3514 year: 1995 end-page: 3516 ident: CR50 article-title: Perforin dependence of natural killer cell-mediated tumor control publication-title: Eur J Immunol doi: 10.1002/eji.1830251246 – volume: 8 start-page: 677 year: 2011 end-page: 688 ident: CR190 article-title: Noninvasive cell-tracking methods publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2011.141 – volume: 7 start-page: 329 year: 2007 end-page: 339 ident: CR46 article-title: Prospects for the use of NK cells in immunotherapy of human cancer publication-title: Nat Rev Immunol doi: 10.1038/nri2073 – volume: 27 start-page: 305 year: 1978 end-page: 377 ident: CR35 article-title: Natural cell-mediated immunity publication-title: Adv Cancer Res doi: 10.1016/S0065-230X(08)60936-7 – volume: 57 start-page: 1541 year: 2008 end-page: 1552 ident: CR133 article-title: NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-008-0492-7 – volume: 13 start-page: 98 year: 2011 end-page: 107 ident: CR201 article-title: A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer publication-title: Cytotherapy doi: 10.3109/14653249.2010.515582 – volume: 12 start-page: 1565 year: 1998 end-page: 1572 ident: CR78 article-title: Induction of sensitivity to NK-mediated cytotoxicity by TNF-alpha treatment: possible role of ICAM-3 and CD44 publication-title: Leukemia doi: 10.1038/sj.leu.2401145 – volume: 68 start-page: 8049 year: 2008 end-page: 8057 ident: CR111 article-title: Potent and activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-2268 – volume: 6 start-page: 56 year: 2012 end-page: 66 ident: CR126 article-title: Natural killer cell lines in tumor immunotherapy publication-title: Front Med doi: 10.1007/s11684-012-0177-7 – volume: 14 start-page: 1131 year: 2012 end-page: 1143 ident: CR197 article-title: Large-scale expansion and characterization of natural killer cells for clinical applications publication-title: Cytotherapy doi: 10.3109/14653249.2012.700767 – volume: 18 start-page: 2021 year: 2008 end-page: 2032 ident: CR193 article-title: Cell tracking with optical imaging publication-title: Eur Radiol doi: 10.1007/s00330-008-0984-z – volume: 100 start-page: 1265 year: 2002 end-page: 1273 ident: CR148 article-title: Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction publication-title: Blood – volume: 2 start-page: 850 year: 2002 end-page: 861 ident: CR40 article-title: New aspects of natural-killer-cell surveillance and therapy of cancer publication-title: Nat Rev Cancer doi: 10.1038/nrc928 – volume: 92 start-page: 697 year: 2001 end-page: 702 ident: CR188 article-title: NK cells are essential for effective BCG immunotherapy publication-title: Int J Cancer doi: 10.1002/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z – volume: 193 start-page: 661 year: 2001 end-page: 670 ident: CR69 article-title: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis publication-title: J Exp Med doi: 10.1084/jem.193.6.661 – volume: 9 start-page: 390 year: 2002 end-page: 398 ident: CR146 article-title: Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition . publication-title: Cancer Gene Ther doi: 10.1038/sj.cgt.7700453 – volume: 8 start-page: 433 year: 2011 end-page: 440 ident: CR32 article-title: HMBOX1 negatively regulates NK cell functions by suppressing the NKG2D/DAP10 signaling pathway publication-title: Cell Mol Immunol doi: 10.1038/cmi.2011.20 – volume: 92 start-page: 4248 year: 1998 end-page: 4255 ident: CR55 article-title: Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells publication-title: Blood – volume: 149 start-page: 135 year: 2010 end-page: 142 ident: CR109 article-title: Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia publication-title: Pain doi: 10.1016/j.pain.2010.01.024 – volume: 29 start-page: 1157 year: 2001 end-page: 1168 ident: CR24 article-title: The biology of natural killer cells in cancer, infection, and pregnancy publication-title: Exp Hematol doi: 10.1016/S0301-472X(01)00696-8 – volume: 88 start-page: 577 year: 2000 end-page: 583 ident: CR44 article-title: Prognostic value of intratumoral natural killer cells in gastric carcinoma publication-title: Cancer doi: 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V – volume: 128 start-page: 192 year: 2005 end-page: 203 ident: CR186 article-title: Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2004.05286.x – volume: 40 start-page: 84 year: 2008 end-page: 90 ident: CR172 article-title: NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation publication-title: Blood Cells Mol Dis doi: 10.1016/j.bcmd.2007.06.029 – volume: 2 start-page: 249 year: 1982 end-page: 263 ident: CR22 article-title: The biology of the human natural killer cell publication-title: J Clin Immunol doi: 10.1007/BF00915064 – volume: 33 start-page: 275 year: 2009 end-page: 281 ident: CR181 article-title: Application of tissue-specific NK and NKT cell activity for tumor immunotherapy publication-title: J Autoimmun doi: 10.1016/j.jaut.2009.07.010 – volume: 87 start-page: 2632 year: 1996 end-page: 2640 ident: CR158 article-title: Role of interleukin-15 in the development of human CD56 natural killer cells from CD34 hematopoietic progenitor cells publication-title: Blood – volume: 11 start-page: 5984 year: 2005 end-page: 5992 ident: CR123 article-title: Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-0577 – volume: 21 start-page: 525 year: 2009 end-page: 530 ident: CR125 article-title: Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2009.07.015 – volume: 13 start-page: 98 year: 2011 end-page: 107 ident: CR179 article-title: A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer publication-title: Cytotherapy doi: 10.3109/14653249.2010.515582 – volume: 27 start-page: 5932 year: 2008 end-page: 5943 ident: CR31 article-title: NK cells and cancer immunosurveillance publication-title: Oncogene doi: 10.1038/onc.2008.267 – volume: 10 start-page: 535 year: 2001 end-page: 544 ident: CR131 article-title: Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92 publication-title: J Hematother Stem Cell Res doi: 10.1089/15258160152509145 – volume: 97 start-page: 2731 year: 2000 end-page: 2736 ident: CR39 article-title: natural killer cell activities revealed by natural killer cell-deficient mice publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.050588297 – volume: 60 start-page: 1195 year: 2011 end-page: 1205 ident: CR182 article-title: Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-011-1050-2 – volume: 93 start-page: 1453 year: 1996 end-page: 1457 ident: CR25 article-title: Physical and functional independency of p70 and p58 natural killer (NK) cell receptors for HLA class I: their role in the definition of different groups of alloreactive NK cell clones publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.93.4.1453 – volume: 5 start-page: 163 year: 2005 end-page: 172 ident: CR151 article-title: Natural killer cells: can they be useful as adoptive immunotherapy for cancer? publication-title: Expert Opin Biol Ther doi: 10.1517/14712598.5.2.163 – volume: 5 start-page: 259 year: 2003 end-page: 272 ident: CR170 article-title: expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy publication-title: Cytotherapy doi: 10.1080/14653240310001523 – volume: 67 start-page: 188 year: 2006 end-page: 195 ident: CR7 article-title: Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients publication-title: Hum Immunol doi: 10.1016/j.humimm.2006.02.008 – volume: 358 start-page: 66 year: 1992 end-page: 70 ident: CR28 article-title: MHC class I alloantigen specificity of Ly-49 IL-2-activated natural killer cells publication-title: Nature doi: 10.1038/358066a0 – volume: 46 start-page: 167 year: 2009 end-page: 189 ident: CR12 article-title: Cancer immunotherapy publication-title: Crit Rev Clin Lab Sci doi: 10.1080/10408360902937809 – volume: 89 start-page: 625 year: 2011 end-page: 638 ident: CR122 article-title: Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting publication-title: J Leukoc Biol doi: 10.1189/jlb.0710422 – volume: 171 start-page: 608 year: 2003 end-page: 615 ident: CR92 article-title: IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma publication-title: J Immunol doi: 10.4049/jimmunol.171.2.608 – volume: 16 start-page: 1043 year: 2007 end-page: 1051 ident: CR153 article-title: Generation of natural killer cells from serum-free, expanded human umbilical cord blood CD34 cells publication-title: Stem Cells Dev doi: 10.1089/scd.2007.0033 – volume: 7 start-page: e30264 year: 2012 ident: CR168 article-title: Membrane-bound IL-21 promotes sustained proliferation of human natural killer cells publication-title: PLoS One doi: 10.1371/journal.pone.0030264 – volume: 134 start-page: 4267 year: 1985 end-page: 4275 ident: CR67 article-title: Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver publication-title: J Immunol – volume: 109 start-page: 3603 year: 2007 end-page: 3606 ident: CR105 article-title: Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors publication-title: Blood doi: 10.1182/blood-2006-05-024315 – volume: 24 start-page: 257 year: 2006 end-page: 286 ident: CR17 article-title: Natural killer cell developmental pathways: a question of balance publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.24.021605.090700 – volume: 11 start-page: 645 year: 2011 end-page: 657 ident: CR34 article-title: NK cell development, homeostasis and function: parallels with CD8 T cells publication-title: Nat Rev Immunol doi: 10.1038/nri3044 – volume: 319 start-page: 675 year: 1986 end-page: 678 ident: CR48 article-title: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy publication-title: Nature doi: 10.1038/319675a0 – volume: 313 start-page: 1485 year: 1985 end-page: 1492 ident: CR174 article-title: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer publication-title: N Engl J Med doi: 10.1056/NEJM198512053132327 – volume: 99 start-page: 1259 year: 2002 end-page: 1266 ident: CR62 article-title: Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide publication-title: Blood doi: 10.1182/blood.V99.4.1259 – volume: 268 start-page: 405 year: 1995 end-page: 408 ident: CR29 article-title: Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells publication-title: Science doi: 10.1126/science.7716543 – volume: 1 start-page: 41 year: 2001 end-page: 49 ident: CR23 article-title: Natural killer cells, viruses and cancer publication-title: Nat Rev Immunol doi: 10.1038/35095564 – volume: 29 start-page: 135 year: 1999 end-page: 140 ident: CR139 article-title: Protein-bound polysaccharide (PSK) induces cytotoxic activity in the NKL human natural killer cell line publication-title: Int J Clin Lab Res doi: 10.1007/s005990050079 – volume: 408 start-page: 57 year: 2000 end-page: 63 ident: CR117 article-title: Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function publication-title: Nature doi: 10.1038/35040504 – volume: 97 start-page: 192 year: 2001 end-page: 197 ident: CR61 article-title: Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis publication-title: Blood doi: 10.1182/blood.V97.1.192 – volume: 118 start-page: 3273 year: 2011 end-page: 3279 ident: CR177 article-title: Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients publication-title: Blood doi: 10.1182/blood-2011-01-329508 – volume: 5 start-page: 363 year: 2005 end-page: 374 ident: CR27 article-title: A new self: MHC-class-I-independent natural-killer-cell self-tolerance publication-title: Nat Rev Immunol doi: 10.1038/nri1603 – volume: 9 start-page: 72 year: 2004 end-page: 81 ident: CR4 article-title: Anti-cytokine Ab immune therapy: present status and perspectives publication-title: Drug Discov Today doi: 10.1016/S1359-6446(03)02955-6 – volume: 10 start-page: 3699 year: 2004 end-page: 3707 ident: CR175 article-title: Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-03-0683 – volume: 356 start-page: 1795 year: 2000 end-page: 1799 ident: CR42 article-title: Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population publication-title: Lancet doi: 10.1016/S0140-6736(00)03231-1 – volume: 180 start-page: 6392 year: 2008 end-page: 6401 ident: CR124 article-title: Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy publication-title: J Immunol doi: 10.4049/jimmunol.180.9.6392 – volume: 169 start-page: 4098 year: 2002 end-page: 4102 ident: CR8 article-title: Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding publication-title: J Immunol doi: 10.4049/jimmunol.169.8.4098 – volume: 79 start-page: 2320 year: 1997 end-page: 2328 ident: CR43 article-title: The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P – volume: 172 start-page: 2048 year: 2004 end-page: 2058 ident: CR118 article-title: IL-21 induces the functional maturation of murine NK cells publication-title: J Immunol doi: 10.4049/jimmunol.172.4.2048 – volume: 113 start-page: 3735 year: 2009 end-page: 3743 ident: CR112 article-title: The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates publication-title: Blood doi: 10.1182/blood-2008-10-182048 – volume: 114 start-page: 3513 year: 2009 end-page: 3523 ident: CR160 article-title: Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells publication-title: Blood doi: 10.1182/blood-2009-03-191304 – volume: 16 start-page: 1107 year: 2010 end-page: 1114 ident: CR178 article-title: Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2010.02.018 – volume: 214 start-page: 73 year: 2006 end-page: 91 ident: CR71 article-title: Activation, coactivation, and costimulation of resting human natural killer cells publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2006.00457.x – volume: 131 start-page: 1024 year: 1983 end-page: 1027 ident: CR37 article-title: role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats publication-title: J Immunol – volume: 91 start-page: 3850 year: 1998 end-page: 3861 ident: CR140 article-title: Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization and . publication-title: Blood – volume: 11 start-page: 658 year: 2011 end-page: 671 ident: CR180 article-title: Organ-specific features of natural killer cells publication-title: Nat Rev Immunol doi: 10.1038/nri3065 – volume: 29 start-page: 1390 year: 1999 end-page: 1396 ident: CR68 article-title: Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12 publication-title: Eur J Immunol doi: 10.1002/(SICI)1521-4141(199904)29:04<1390::AID-IMMU1390>3.0.CO;2-C – volume: 76 start-page: 467 year: 2010 end-page: 475 ident: CR167 article-title: expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15 publication-title: Tissue Antigens doi: 10.1111/j.1399-0039.2010.01535.x – volume: 59 start-page: 1781 year: 2010 end-page: 1789 ident: CR104 article-title: A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-010-0904-3 – volume: 42 start-page: 128 year: 2008 end-page: 136 ident: CR137 article-title: Interleukin-15 improves cytotoxicity of natural killer cells up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation publication-title: Cytokine doi: 10.1016/j.cyto.2008.01.003 – volume: 117 start-page: 2423 year: 2011 end-page: 2432 ident: CR120 article-title: CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies publication-title: Blood doi: 10.1182/blood-2010-08-301945 – volume: 266 start-page: 154 year: 2009 end-page: 181 ident: CR60 article-title: Natural killer cell-based immunotherapy in cancer: current insights and future prospects publication-title: J Intern Med doi: 10.1111/j.1365-2796.2009.02121.x – volume: 17 start-page: 6287 year: 2011 end-page: 6297 ident: CR176 article-title: Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-1347 – volume: 106 start-page: 12879 year: 2009 end-page: 12884 ident: CR184 article-title: Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition . publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0901653106 – volume: 12 start-page: 323 year: 2000 end-page: 329 ident: CR54 article-title: Proapoptotic functions of cytotoxic lymphocyte granule constituents and publication-title: Curr Opin Immunol doi: 10.1016/S0952-7915(00)00094-7 – volume: 6 start-page: e20740 year: 2011 ident: CR155 article-title: Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process publication-title: PLoS One doi: 10.1371/journal.pone.0020740 – volume: 19 start-page: 561 year: 2003 end-page: 569 ident: CR73 article-title: Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses publication-title: Immunity doi: 10.1016/S1074-7613(03)00264-4 – volume: 93 start-page: 1612 year: 1999 end-page: 1621 ident: CR70 article-title: Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12 publication-title: Blood – volume: 90 start-page: 716 year: 1997 end-page: 725 ident: CR106 article-title: Signaling pathways regulating CD44-dependent cytolysis in natural killer cells publication-title: Blood – volume: 167 start-page: 2068 year: 2001 end-page: 2073 ident: CR56 article-title: A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells publication-title: J Immunol doi: 10.4049/jimmunol.167.4.2068 – volume: 51 start-page: 295 year: 2004 end-page: 318 ident: CR80 article-title: Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma publication-title: Adv Pharmacol doi: 10.1016/S1054-3589(04)51013-X – volume: 5 start-page: e9221 year: 2010 ident: CR154 article-title: High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy publication-title: PLoS One doi: 10.1371/journal.pone.0009221 – volume: 3 start-page: 501 year: 1984 end-page: 511 ident: CR85 article-title: Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2 publication-title: J Biol Response Mod – volume: 99 start-page: 3661 year: 2002 end-page: 3667 ident: CR79 article-title: Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia publication-title: Blood doi: 10.1182/blood.V99.10.3661 – volume: 82 start-page: 355 year: 2006 end-page: 361 ident: CR135 article-title: Irradiated KHYG-1 retains cytotoxicity: potential for adoptive immunotherapy with a natural killer cell line publication-title: Int J Radiat Biol doi: 10.1080/09553000600649653 – volume: 25 start-page: 475 year: 1980 end-page: 486 ident: CR36 article-title: natural reactivity of mice against tumor cells publication-title: Int J Cancer doi: 10.1002/ijc.2910250409 – volume: 16 start-page: 115 year: 2006 end-page: 123 ident: CR6 article-title: Regulatory T cells in immune surveillance and treatment of cancer publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2005.11.005 – volume: 195 start-page: 327 year: 2002 end-page: 333 ident: CR77 article-title: Reciprocal activating interaction between natural killer cells and dendritic cells publication-title: J Exp Med doi: 10.1084/jem.20010938 – volume: 28 start-page: 175 year: 2005 end-page: 182 ident: CR102 article-title: Natural killer cell alloreactivity for leukemia therapy publication-title: J Immunother doi: 10.1097/01.cji.0000161395.88959.1f – volume: 5 start-page: 112 year: 1975 end-page: 117 ident: CR15 article-title: “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype publication-title: Eur J Immunol doi: 10.1002/eji.1830050208 – volume: 33 start-page: 159 year: 2005 end-page: 164 ident: CR144 article-title: Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells publication-title: Exp Hematol doi: 10.1016/j.exphem.2004.11.003 – volume: 29 start-page: 134 year: 2010 ident: CR199 article-title: expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity publication-title: J Exp Clin Cancer Res doi: 10.1186/1756-9966-29-134 – volume: 32 start-page: 622 year: 2009 end-page: 631 ident: CR119 article-title: Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma publication-title: J Immunother doi: 10.1097/CJI.0b013e3181ab23f1 – volume: 90 start-page: 127 year: 2003 end-page: 156 ident: CR41 article-title: Natural killer cells and cancer publication-title: Adv Cancer Res doi: 10.1016/S0065-230X(03)90004-2 – volume: 29 start-page: 301 year: 2005 end-page: 306 ident: CR147 article-title: Specific targeting of CD33 leukemia cells by a natural killer cell line modified with a chimeric receptor publication-title: Leuk Res doi: 10.1016/j.leukres.2004.07.005 – volume: 10 start-page: 1359 year: 1999 end-page: 1373 ident: CR143 article-title: Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy publication-title: Hum Gene Ther doi: 10.1089/10430349950018030 – volume: 53 start-page: 117 year: 1994 end-page: 124 ident: CR88 article-title: Treatment of advanced renal cell carcinoma using regional arterial administration of lymphokine-activated killer cells in combination with low doses of rIL-2 publication-title: Urol Int doi: 10.1159/000282651 – volume: 110 start-page: 983 year: 2002 end-page: 992 ident: CR113 article-title: IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells publication-title: J Clin Invest doi: 10.1172/JCI0215950 – volume: 7 start-page: 94 year: 2001 end-page: 100 ident: CR58 article-title: Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells publication-title: Nat Med doi: 10.1038/83416 – volume: 6 start-page: 136 year: 1992 end-page: 141 ident: CR128 article-title: Detection of Epstein-Barr virus genome in natural-killer-like cell line, YT publication-title: Leukemia – volume: 106 start-page: 2252 year: 2005 end-page: 2258 ident: CR30 article-title: Natural-killer cells and dendritic cells: “l'union fait la force” publication-title: Blood doi: 10.1182/blood-2005-03-1154 – volume: 168 start-page: 1356 year: 2002 end-page: 1361 ident: CR59 article-title: Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice publication-title: J Immunol doi: 10.4049/jimmunol.168.3.1356 – volume: 52 start-page: 59 year: 2003 end-page: 64 ident: CR138 article-title: Different regulation of PKC isoenzymes and MAPK by PSK and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line publication-title: Cancer Immunol Immunother – volume: 295 start-page: 2097 year: 2002 end-page: 2100 ident: CR101 article-title: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants publication-title: Science doi: 10.1126/science.1068440 – volume: 2011 start-page: 379123 year: 2011 ident: CR108 article-title: Clinical cancer therapy by NK cells antibody-dependent cell-mediated cytotoxicity publication-title: J Biomed Biotechnol doi: 10.1155/2011/379123 – volume: 66 start-page: 2520 year: 2006 end-page: 2526 ident: CR9 article-title: Proteolytic release of soluble UL16-binding protein 2 from tumor cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-2520 – volume: 70 start-page: 6109 year: 2010 end-page: 6113 ident: CR189 article-title: Monitoring of natural killer cell immunotherapy using noninvasive imaging modalities publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-3774 – ident: CR83 – volume: 172 start-page: 1333 year: 2004 end-page: 1339 ident: CR21 article-title: NK cell compartments and their activation by dendritic cells publication-title: J Immunol doi: 10.4049/jimmunol.172.3.1333 – volume: 59 start-page: 1781 year: 2010 end-page: 1789 ident: CR196 article-title: A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-010-0904-3 – volume: 2 start-page: 35 year: 2002 end-page: 43 ident: CR5 article-title: Dendritic cell maturation in active immunotherapy strategies publication-title: Expert Opin Biol Ther doi: 10.1517/14712598.2.1.35 – volume: 105 start-page: 3051 year: 2005 end-page: 3057 ident: CR103 article-title: Successful adoptive transfer and expansion of human haploidentical NK cells in patients with cancer publication-title: Blood doi: 10.1182/blood-2004-07-2974 – volume: 11 start-page: 341 year: 2009 end-page: 355 ident: CR164 article-title: Clinical-grade -expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells publication-title: Cytotherapy doi: 10.1080/14653240902807034 – volume: 5 start-page: 1260 year: 2004 end-page: 1265 ident: CR72 article-title: Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming publication-title: Nat Immunol doi: 10.1038/ni1138 – volume: 76 start-page: 840 year: 1995 end-page: 852 ident: CR90 article-title: Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma publication-title: Cancer doi: 10.1002/1097-0142(19950901)76:5<840::AID-CNCR2820760519>3.0.CO;2-R – volume: 114 start-page: 2667 year: 2009 end-page: 2677 ident: CR183 article-title: Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells publication-title: Blood doi: 10.1182/blood-2009-02-206532 – volume: 625 start-page: 41 year: 2009 end-page: 54 ident: CR1 article-title: Immunotherapy of cancer publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2009.09.067 – volume: 7 start-page: 16 year: 2005 end-page: 22 ident: CR132 article-title: Natural killer cell-based immunotherapeutic strategies publication-title: Cytotherapy doi: 10.1016/S1465-3249(05)70785-4 – volume: 11 start-page: 1097 year: 2004 end-page: 1106 ident: CR145 article-title: Characterization of stem cell factor gene-modified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunotherapy publication-title: Oncol Rep – volume: 29 start-page: 104 year: 2001 end-page: 113 ident: CR156 article-title: expansion of CD56 cytotoxic cells from human umbilical cord blood publication-title: Exp Hematol doi: 10.1016/S0301-472X(00)00617-2 – volume: 188 start-page: 1611 year: 1998 end-page: 1619 ident: CR51 article-title: An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum publication-title: J Exp Med doi: 10.1084/jem.188.9.1611 – volume: 9 start-page: 503 year: 2008 end-page: 510 ident: CR26 article-title: Functions of natural killer cells publication-title: Nat Immunol doi: 10.1038/ni1582 – volume: 22 start-page: 633 year: 2001 end-page: 640 ident: CR19 article-title: The biology of human natural killer-cell subsets publication-title: Trends Immunol doi: 10.1016/S1471-4906(01)02060-9 – volume: 12 start-page: 500 issue: 6 year: 2011 end-page: 508 ident: CR33 article-title: Natural killer cell memory publication-title: Nature Immunology doi: 10.1038/ni.2032 – volume: 30A start-page: 103 year: 1994 end-page: 105 ident: CR91 article-title: Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases publication-title: Eur J Cancer A doi: 10.1016/S0959-8049(05)80028-0 – volume: 24 start-page: 487 year: 2005 end-page: 499 ident: CR107 article-title: Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies publication-title: Cancer Metastasis Rev doi: 10.1007/s10555-005-6192-2 – volume: 175 start-page: 5095 year: 2005 end-page: 5103 ident: CR162 article-title: Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity publication-title: J Immunol doi: 10.4049/jimmunol.175.8.5095 – volume: 9 start-page: 11 year: 2012 end-page: 19 ident: CR13 article-title: Bone marrow and the control of immunity publication-title: Cell Mol Immunol doi: 10.1038/cmi.2011.47 – volume: 23 start-page: 154 year: 2000 end-page: 160 ident: CR98 article-title: Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer publication-title: J Immunother doi: 10.1097/00002371-200001000-00018 – volume: 12 start-page: 750 year: 2010 end-page: 763 ident: CR166 article-title: Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients publication-title: Cytotherapy doi: 10.3109/14653241003786155 – volume: 172 start-page: 6598 year: 2004 end-page: 6606 ident: CR11 article-title: Activation-induced cell death limits effector function of CD4 tumor-specific T cells publication-title: J Immunol doi: 10.4049/jimmunol.172.11.6598 – volume: 47 start-page: 5725 year: 1987 end-page: 5732 ident: CR65 article-title: Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease publication-title: Cancer Res – volume: 14 start-page: 593 year: 2012 end-page: 605 ident: CR198 article-title: Synergistic cytotoxicity of expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2012.09.014 – volume: 13 start-page: 155 year: 2002 end-page: 168 ident: CR84 article-title: Interleukin-12 in anti-tumor immunity and immunotherapy publication-title: Cytokine Growth Factor Rev doi: 10.1016/S1359-6101(01)00032-6 – volume: 113 start-page: 6094 year: 2009 end-page: 6101 ident: CR163 article-title: Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity publication-title: Blood doi: 10.1182/blood-2008-06-165225 – volume: 16 start-page: 216 year: 1975 end-page: 229 ident: CR14 article-title: Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity publication-title: Int J Cancer doi: 10.1002/ijc.2910160204 – volume: 138 start-page: 3566 year: 1987 end-page: 3572 ident: CR115 article-title: Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies publication-title: J Immunol – volume: 156 start-page: 147 year: 2010 end-page: 154 ident: CR161 article-title: Pluripotent stem cell-derived natural killer cells for cancer therapy publication-title: Transl Res doi: 10.1016/j.trsl.2010.07.008 – volume: 10 start-page: 265 year: 2008 end-page: 274 ident: CR142 article-title: Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL publication-title: Cytotherapy doi: 10.1080/14653240801965156 – volume: 105 start-page: 721 year: 2005 end-page: 727 ident: CR94 article-title: Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance publication-title: Blood doi: 10.1182/blood-2003-12-4187 – volume: 9 start-page: 310 year: 2012 end-page: 320 ident: CR152 article-title: Generation of natural killer cells from hematopoietic stem cells for immunotherapy publication-title: Cell Mol Immunol doi: 10.1038/cmi.2012.17 – volume: 4 start-page: 379 year: 1992 end-page: 388 ident: CR10 article-title: Activation-induced apoptosis in lymphoid systems publication-title: Semin Immunol – volume: 163 start-page: 1906 year: 1999 end-page: 1913 ident: CR57 article-title: Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells publication-title: J Immunol – volume: 9 start-page: 193 year: 2012 end-page: 194 ident: CR16 article-title: Single line or parallel lines: NK cell differentiation driven by T-bet and Eomes publication-title: Cell Mol Immunol doi: 10.1038/cmi.2012.8 – volume: 26 start-page: 1113 year: 2006 end-page: 1134 ident: CR2 article-title: Molecular immunological approaches to biotherapy of human cancers—a review, hypothesis and implications publication-title: Anticancer Res – volume: 24 start-page: 406 year: 1996 end-page: 415 ident: CR136 article-title: Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia publication-title: Exp Hematol – volume: 33 start-page: 1160 year: 2005 end-page: 1171 ident: CR134 article-title: KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity publication-title: Exp Hematol doi: 10.1016/j.exphem.2005.06.024 – volume: 220 start-page: 169 year: 2007 end-page: 182 ident: CR18 article-title: The trafficking of natural killer cells publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2007.00563.x – volume: 10 start-page: 200 year: 2010 end-page: 209 ident: CR110 article-title: Anti-GD2 antibody therapy for GD2-expressing tumors publication-title: Curr Cancer Drug Targets doi: 10.2174/156800910791054167 – volume: 51 start-page: 333 year: 2010 end-page: 336 ident: CR194 article-title: PET/MRI: paving the way for the next generation of clinical multimodality imaging applications publication-title: J Nucl Med doi: 10.2967/jnumed.109.061853 – volume: 39 start-page: 193 year: 1994 end-page: 197 ident: CR89 article-title: Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients publication-title: Cancer Immunol Immunother doi: 10.1007/BF01533386 – volume: 32 start-page: 177 year: 2003 end-page: 186 ident: CR100 article-title: IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1704086 – volume: 59 start-page: 1511 year: 2010 end-page: 1519 ident: CR173 article-title: Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-010-0878-1 – volume: 106 start-page: 376 year: 2005 end-page: 383 ident: CR150 article-title: Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells publication-title: Blood doi: 10.1182/blood-2004-12-4797 – volume: 20 start-page: 1731 year: 2011 end-page: 1746 ident: CR127 article-title: Establishment, characterization and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line publication-title: Cell Transplant doi: 10.3727/096368911X580536 – volume: 12 start-page: 1044 year: 2010 end-page: 1055 ident: CR200 article-title: Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor publication-title: Cytotherapy doi: 10.3109/14653249.2010.504770 – volume: 3 start-page: 34 year: 1997 end-page: 44 ident: CR99 article-title: Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained natural killer cell activity publication-title: Biol Blood Marrow Transplant – volume: 89 start-page: 338 year: 2004 end-page: 347 ident: CR141 article-title: Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy publication-title: Haematologica – volume: 202 start-page: 275 year: 2004 end-page: 293 ident: CR81 article-title: Cytokines in cancer immunity and immunotherapy publication-title: Immunol Rev doi: 10.1111/j.0105-2896.2004.00199.x – volume: 57 start-page: 411 year: 2008 end-page: 423 ident: CR149 article-title: Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-007-0383-3 – volume: 35 start-page: 23 year: 2002 end-page: 28 ident: CR45 article-title: Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer publication-title: Lung Cancer doi: 10.1016/S0169-5002(01)00292-6 – volume: 18 start-page: 991 year: 2009 end-page: 1000 ident: CR121 article-title: The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma publication-title: Expert Opin Investig Drugs doi: 10.1517/13543780903048911 – volume: 369 start-page: 31 year: 1994 end-page: 37 ident: CR53 article-title: Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice publication-title: Nature doi: 10.1038/369031a0 – volume: 178 start-page: 4011 year: 2007 end-page: 4016 ident: CR95 article-title: NK cells and cancer publication-title: J Immunol doi: 10.4049/jimmunol.178.7.4011 – volume: 8 start-page: 2211 year: 2009 end-page: 2220 ident: CR185 article-title: Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR) publication-title: Cancer Biol Ther doi: 10.4161/cbt.8.23.10455 – volume: 109 start-page: 2008 year: 2007 end-page: 2013 ident: CR187 article-title: control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides publication-title: Blood doi: 10.1182/blood-2006-02-002055 – volume: 25 start-page: 475 year: 1980 ident: BFcmi201310_CR36 publication-title: Int J Cancer doi: 10.1002/ijc.2910250409 – volume: 88 start-page: 577 year: 2000 ident: BFcmi201310_CR44 publication-title: Cancer doi: 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V – volume: 138 start-page: 3566 year: 1987 ident: BFcmi201310_CR115 publication-title: J Immunol doi: 10.4049/jimmunol.138.10.3566 – volume: 10 start-page: 625 year: 2008 ident: BFcmi201310_CR171 publication-title: Cytotherapy doi: 10.1080/14653240802301872 – volume: 31 start-page: 403 year: 2004 ident: BFcmi201310_CR191 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-003-1398-4 – volume: 14 start-page: 922 year: 2000 ident: BFcmi201310_CR130 publication-title: Leukemia doi: 10.1038/sj.leu.2401769 – volume: 2011 start-page: 379123 year: 2011 ident: BFcmi201310_CR108 publication-title: J Biomed Biotechnol doi: 10.1155/2011/379123 – volume: 59 start-page: 1511 year: 2010 ident: BFcmi201310_CR173 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-010-0878-1 – volume: 93 start-page: 1453 year: 1996 ident: BFcmi201310_CR25 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.93.4.1453 – volume: 3 start-page: 34 year: 1997 ident: BFcmi201310_CR99 publication-title: Biol Blood Marrow Transplant – volume: 162 start-page: 6658 year: 1999 ident: BFcmi201310_CR52 publication-title: J Immunol doi: 10.4049/jimmunol.162.11.6658 – volume: 87 start-page: 2632 year: 1996 ident: BFcmi201310_CR158 publication-title: Blood doi: 10.1182/blood.V87.7.2632.bloodjournal8772632 – volume: 10 start-page: 1359 year: 1999 ident: BFcmi201310_CR143 publication-title: Hum Gene Ther doi: 10.1089/10430349950018030 – volume: 214 start-page: 73 year: 2006 ident: BFcmi201310_CR71 publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2006.00457.x – volume: 76 start-page: 467 year: 2010 ident: BFcmi201310_CR167 publication-title: Tissue Antigens doi: 10.1111/j.1399-0039.2010.01535.x – volume: 193 start-page: 661 year: 2001 ident: BFcmi201310_CR69 publication-title: J Exp Med doi: 10.1084/jem.193.6.661 – volume: 51 start-page: 295 year: 2004 ident: BFcmi201310_CR80 publication-title: Adv Pharmacol doi: 10.1016/S1054-3589(04)51013-X – volume: 13 start-page: 155 year: 2002 ident: BFcmi201310_CR84 publication-title: Cytokine Growth Factor Rev doi: 10.1016/S1359-6101(01)00032-6 – ident: BFcmi201310_CR83 – volume: 100 start-page: 1265 year: 2002 ident: BFcmi201310_CR148 publication-title: Blood doi: 10.1182/blood.V100.4.1265.h81602001265_1265_1273 – volume: 46 start-page: 167 year: 2009 ident: BFcmi201310_CR12 publication-title: Crit Rev Clin Lab Sci doi: 10.1080/10408360902937809 – volume: 29 start-page: 135 year: 1999 ident: BFcmi201310_CR139 publication-title: Int J Clin Lab Res doi: 10.1007/s005990050079 – volume: 18 start-page: 991 year: 2009 ident: BFcmi201310_CR121 publication-title: Expert Opin Investig Drugs doi: 10.1517/13543780903048911 – volume: 14 start-page: 593 year: 2012 ident: BFcmi201310_CR198 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2012.09.014 – volume: 9 start-page: 45 year: 2012 ident: BFcmi201310_CR75 publication-title: Cell Mol Immunol doi: 10.1038/cmi.2011.23 – volume: 89 start-page: 338 year: 2004 ident: BFcmi201310_CR141 publication-title: Haematologica – volume: 5 start-page: 163 year: 2005 ident: BFcmi201310_CR151 publication-title: Expert Opin Biol Ther doi: 10.1517/14712598.5.2.163 – volume: 156 start-page: 147 year: 2010 ident: BFcmi201310_CR161 publication-title: Transl Res doi: 10.1016/j.trsl.2010.07.008 – volume: 195 start-page: 335 year: 2002 ident: BFcmi201310_CR76 publication-title: J Exp Med doi: 10.1084/jem.20010934 – volume: 8 start-page: 2211 year: 2009 ident: BFcmi201310_CR185 publication-title: Cancer Biol Ther doi: 10.4161/cbt.8.23.10455 – volume: 59 start-page: 1781 year: 2010 ident: BFcmi201310_CR196 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-010-0904-3 – volume: 172 start-page: 6598 year: 2004 ident: BFcmi201310_CR11 publication-title: J Immunol doi: 10.4049/jimmunol.172.11.6598 – volume: 24 start-page: 257 year: 2006 ident: BFcmi201310_CR17 publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.24.021605.090700 – volume: 9 start-page: 11 year: 2012 ident: BFcmi201310_CR13 publication-title: Cell Mol Immunol doi: 10.1038/cmi.2011.47 – volume: 98 start-page: 10716 year: 2001 ident: BFcmi201310_CR159 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.191362598 – volume: 5 start-page: 1260 year: 2004 ident: BFcmi201310_CR72 publication-title: Nat Immunol doi: 10.1038/ni1138 – volume: 163 start-page: 1473 year: 1999 ident: BFcmi201310_CR64 publication-title: J Immunol doi: 10.4049/jimmunol.163.3.1473 – volume: 14 start-page: 1131 year: 2012 ident: BFcmi201310_CR197 publication-title: Cytotherapy doi: 10.3109/14653249.2012.700767 – volume: 12 start-page: 750 year: 2010 ident: BFcmi201310_CR166 publication-title: Cytotherapy doi: 10.3109/14653241003786155 – volume: 43 start-page: 464 year: 2002 ident: BFcmi201310_CR3 publication-title: J Small Anim Pract doi: 10.1111/j.1748-5827.2002.tb00015.x – volume: 27 start-page: 305 year: 1978 ident: BFcmi201310_CR35 publication-title: Adv Cancer Res doi: 10.1016/S0065-230X(08)60936-7 – volume: 1 start-page: 209 year: 2001 ident: BFcmi201310_CR93 publication-title: Nat Rev Immunol doi: 10.1038/35105075 – volume: 105 start-page: 721 year: 2005 ident: BFcmi201310_CR94 publication-title: Blood doi: 10.1182/blood-2003-12-4187 – volume: 163 start-page: 1906 year: 1999 ident: BFcmi201310_CR57 publication-title: J Immunol doi: 10.4049/jimmunol.163.4.1906 – volume: 16 start-page: 115 year: 2006 ident: BFcmi201310_CR6 publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2005.11.005 – volume: 9 start-page: 503 year: 2008 ident: BFcmi201310_CR26 publication-title: Nat Immunol doi: 10.1038/ni1582 – volume: 10 start-page: 535 year: 2001 ident: BFcmi201310_CR131 publication-title: J Hematother Stem Cell Res doi: 10.1089/15258160152509145 – volume: 4 start-page: 379 year: 1992 ident: BFcmi201310_CR10 publication-title: Semin Immunol – volume: 171 start-page: 608 year: 2003 ident: BFcmi201310_CR92 publication-title: J Immunol doi: 10.4049/jimmunol.171.2.608 – volume: 172 start-page: 2048 year: 2004 ident: BFcmi201310_CR118 publication-title: J Immunol doi: 10.4049/jimmunol.172.4.2048 – volume: 13 start-page: 98 year: 2011 ident: BFcmi201310_CR179 publication-title: Cytotherapy doi: 10.3109/14653249.2010.515582 – volume: 268 start-page: 405 year: 1995 ident: BFcmi201310_CR29 publication-title: Science doi: 10.1126/science.7716543 – volume: 90 start-page: 127 year: 2003 ident: BFcmi201310_CR41 publication-title: Adv Cancer Res doi: 10.1016/S0065-230X(03)90004-2 – volume: 114 start-page: 3513 year: 2009 ident: BFcmi201310_CR160 publication-title: Blood doi: 10.1182/blood-2009-03-191304 – volume: 2 start-page: 850 year: 2002 ident: BFcmi201310_CR40 publication-title: Nat Rev Cancer doi: 10.1038/nrc928 – volume: 266 start-page: 154 year: 2009 ident: BFcmi201310_CR60 publication-title: J Intern Med doi: 10.1111/j.1365-2796.2009.02121.x – volume: 6 start-page: e20740 year: 2011 ident: BFcmi201310_CR155 publication-title: PLoS One doi: 10.1371/journal.pone.0020740 – volume: 106 start-page: 2252 year: 2005 ident: BFcmi201310_CR30 publication-title: Blood doi: 10.1182/blood-2005-03-1154 – volume: 97 start-page: 192 year: 2001 ident: BFcmi201310_CR61 publication-title: Blood doi: 10.1182/blood.V97.1.192 – volume: 9 start-page: 390 year: 2002 ident: BFcmi201310_CR146 publication-title: Cancer Gene Ther doi: 10.1038/sj.cgt.7700453 – volume: 356 start-page: 1795 year: 2000 ident: BFcmi201310_CR42 publication-title: Lancet doi: 10.1016/S0140-6736(00)03231-1 – volume: 57 start-page: 411 year: 2008 ident: BFcmi201310_CR149 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-007-0383-3 – volume: 313 start-page: 1485 year: 1985 ident: BFcmi201310_CR174 publication-title: N Engl J Med doi: 10.1056/NEJM198512053132327 – volume: 29 start-page: 1157 year: 2001 ident: BFcmi201310_CR24 publication-title: Exp Hematol doi: 10.1016/S0301-472X(01)00696-8 – volume: 6 start-page: 136 year: 1992 ident: BFcmi201310_CR128 publication-title: Leukemia – volume: 12 start-page: 1565 year: 1998 ident: BFcmi201310_CR78 publication-title: Leukemia doi: 10.1038/sj.leu.2401145 – volume: 113 start-page: 6094 year: 2009 ident: BFcmi201310_CR163 publication-title: Blood doi: 10.1182/blood-2008-06-165225 – volume: 92 start-page: 1374 year: 1998 ident: BFcmi201310_CR129 publication-title: Blood doi: 10.1182/blood.V92.4.1374.416a33_1374_1383 – volume: 8 start-page: 677 year: 2011 ident: BFcmi201310_CR190 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2011.141 – volume: 12 start-page: 323 year: 2000 ident: BFcmi201310_CR54 publication-title: Curr Opin Immunol doi: 10.1016/S0952-7915(00)00094-7 – volume: 3 start-page: 83 year: 2002 ident: BFcmi201310_CR74 publication-title: Nat Immunol doi: 10.1038/ni746 – volume: 172 start-page: 1333 year: 2004 ident: BFcmi201310_CR21 publication-title: J Immunol doi: 10.4049/jimmunol.172.3.1333 – volume: 13 start-page: 98 year: 2011 ident: BFcmi201310_CR201 publication-title: Cytotherapy doi: 10.3109/14653249.2010.515582 – volume: 29 start-page: 301 year: 2005 ident: BFcmi201310_CR147 publication-title: Leuk Res doi: 10.1016/j.leukres.2004.07.005 – volume: 93 start-page: 3876 year: 1999 ident: BFcmi201310_CR63 publication-title: Blood doi: 10.1182/blood.V93.11.3876.411k25_3876_3884 – volume: 162 start-page: 1745 year: 1985 ident: BFcmi201310_CR47 publication-title: J Exp Med doi: 10.1084/jem.162.6.1745 – volume: 89 start-page: 625 year: 2011 ident: BFcmi201310_CR122 publication-title: J Leukoc Biol doi: 10.1189/jlb.0710422 – volume: 60 start-page: 1195 year: 2011 ident: BFcmi201310_CR182 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-011-1050-2 – volume: 69 start-page: 4010 year: 2009 ident: BFcmi201310_CR165 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-3712 – volume: 202 start-page: 275 year: 2004 ident: BFcmi201310_CR81 publication-title: Immunol Rev doi: 10.1111/j.0105-2896.2004.00199.x – volume: 32 start-page: 177 year: 2003 ident: BFcmi201310_CR100 publication-title: Bone Marrow Transplant doi: 10.1038/sj.bmt.1704086 – volume: 97 start-page: 2731 year: 2000 ident: BFcmi201310_CR39 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.050588297 – volume: 11 start-page: 341 year: 2009 ident: BFcmi201310_CR164 publication-title: Cytotherapy doi: 10.1080/14653240902807034 – volume: 23 start-page: 154 year: 2000 ident: BFcmi201310_CR98 publication-title: J Immunother doi: 10.1097/00002371-200001000-00018 – volume: 91 start-page: 3850 year: 1998 ident: BFcmi201310_CR140 publication-title: Blood doi: 10.1182/blood.V91.10.3850 – volume: 625 start-page: 41 year: 2009 ident: BFcmi201310_CR1 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2009.09.067 – volume: 33 start-page: 275 year: 2009 ident: BFcmi201310_CR181 publication-title: J Autoimmun doi: 10.1016/j.jaut.2009.07.010 – volume: 220 start-page: 169 year: 2007 ident: BFcmi201310_CR18 publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2007.00563.x – volume: 39 start-page: 193 year: 1994 ident: BFcmi201310_CR89 publication-title: Cancer Immunol Immunother doi: 10.1007/BF01533386 – volume: 52 start-page: 59 year: 2003 ident: BFcmi201310_CR138 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-002-0336-9 – volume: 22 start-page: 633 year: 2001 ident: BFcmi201310_CR19 publication-title: Trends Immunol doi: 10.1016/S1471-4906(01)02060-9 – volume: 30A start-page: 103 year: 1994 ident: BFcmi201310_CR91 publication-title: Eur J Cancer A doi: 10.1016/S0959-8049(05)80028-0 – volume: 168 start-page: 1356 year: 2002 ident: BFcmi201310_CR59 publication-title: J Immunol doi: 10.4049/jimmunol.168.3.1356 – volume: 35 start-page: 23 year: 2002 ident: BFcmi201310_CR45 publication-title: Lung Cancer doi: 10.1016/S0169-5002(01)00292-6 – volume: 5 start-page: 363 year: 2005 ident: BFcmi201310_CR27 publication-title: Nat Rev Immunol doi: 10.1038/nri1603 – volume: 12 start-page: 1044 year: 2010 ident: BFcmi201310_CR200 publication-title: Cytotherapy doi: 10.3109/14653249.2010.504770 – volume: 24 start-page: 1861 year: 2004 ident: BFcmi201310_CR97 publication-title: Anticancer Res – volume: 118 start-page: 3273 year: 2011 ident: BFcmi201310_CR177 publication-title: Blood doi: 10.1182/blood-2011-01-329508 – volume: 2 start-page: 249 year: 1982 ident: BFcmi201310_CR22 publication-title: J Clin Immunol doi: 10.1007/BF00915064 – volume: 70 start-page: 6109 year: 2010 ident: BFcmi201310_CR189 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-3774 – volume: 114 start-page: 2667 year: 2009 ident: BFcmi201310_CR183 publication-title: Blood doi: 10.1182/blood-2009-02-206532 – volume: 59 start-page: 1781 year: 2010 ident: BFcmi201310_CR104 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-010-0904-3 – volume: 67 start-page: 188 year: 2006 ident: BFcmi201310_CR7 publication-title: Hum Immunol doi: 10.1016/j.humimm.2006.02.008 – volume: 92 start-page: 697 year: 2001 ident: BFcmi201310_CR188 publication-title: Int J Cancer doi: 10.1002/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z – volume: 16 start-page: 1043 year: 2007 ident: BFcmi201310_CR153 publication-title: Stem Cells Dev doi: 10.1089/scd.2007.0033 – volume: 10 start-page: 200 year: 2010 ident: BFcmi201310_CR110 publication-title: Curr Cancer Drug Targets doi: 10.2174/156800910791054167 – volume: 117 start-page: 2423 year: 2011 ident: BFcmi201310_CR120 publication-title: Blood doi: 10.1182/blood-2010-08-301945 – volume: 82 start-page: 355 year: 2006 ident: BFcmi201310_CR135 publication-title: Int J Radiat Biol doi: 10.1080/09553000600649653 – volume: 95 start-page: 293 year: 2006 ident: BFcmi201310_CR38 publication-title: Adv Cancer Res doi: 10.1016/S0065-230X(06)95008-8 – volume: 8 start-page: 15 year: 2009 ident: BFcmi201310_CR192 publication-title: Mol Imaging doi: 10.2310/7290.2009.00002 – volume: 68 start-page: 8049 year: 2008 ident: BFcmi201310_CR111 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-2268 – volume: 149 start-page: 135 year: 2010 ident: BFcmi201310_CR109 publication-title: Pain doi: 10.1016/j.pain.2010.01.024 – volume: 18 start-page: 2021 year: 2008 ident: BFcmi201310_CR193 publication-title: Eur Radiol doi: 10.1007/s00330-008-0984-z – volume: 131 start-page: 1024 year: 1983 ident: BFcmi201310_CR37 publication-title: J Immunol doi: 10.4049/jimmunol.131.2.1024 – volume: 7 start-page: e30264 year: 2012 ident: BFcmi201310_CR168 publication-title: PLoS One doi: 10.1371/journal.pone.0030264 – volume: 20 start-page: 1731 year: 2011 ident: BFcmi201310_CR127 publication-title: Cell Transplant doi: 10.3727/096368911X580536 – volume: 319 start-page: 675 year: 1986 ident: BFcmi201310_CR48 publication-title: Nature doi: 10.1038/319675a0 – volume: 169 start-page: 4098 year: 2002 ident: BFcmi201310_CR8 publication-title: J Immunol doi: 10.4049/jimmunol.169.8.4098 – volume: 24 start-page: 487 year: 2005 ident: BFcmi201310_CR107 publication-title: Cancer Metastasis Rev doi: 10.1007/s10555-005-6192-2 – volume: 10 start-page: 3699 year: 2004 ident: BFcmi201310_CR175 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-03-0683 – volume: 32 start-page: 622 year: 2009 ident: BFcmi201310_CR119 publication-title: J Immunother doi: 10.1097/CJI.0b013e3181ab23f1 – volume: 79 start-page: 2320 year: 1997 ident: BFcmi201310_CR43 publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P – volume: 9 start-page: 310 year: 2012 ident: BFcmi201310_CR152 publication-title: Cell Mol Immunol doi: 10.1038/cmi.2012.17 – volume: 99 start-page: 3661 year: 2002 ident: BFcmi201310_CR79 publication-title: Blood doi: 10.1182/blood.V99.10.3661 – volume: 7 start-page: 94 year: 2001 ident: BFcmi201310_CR58 publication-title: Nat Med doi: 10.1038/83416 – volume: 76 start-page: 840 year: 1995 ident: BFcmi201310_CR90 publication-title: Cancer doi: 10.1002/1097-0142(19950901)76:5<840::AID-CNCR2820760519>3.0.CO;2-R – volume: 21 start-page: 525 year: 2009 ident: BFcmi201310_CR125 publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2009.07.015 – volume: 109 start-page: 2008 year: 2007 ident: BFcmi201310_CR187 publication-title: Blood doi: 10.1182/blood-2006-02-002055 – volume: 32 start-page: 1167 year: 2011 ident: BFcmi201310_CR195 publication-title: Biomaterials doi: 10.1016/j.biomaterials.2010.10.013 – volume: 33 start-page: 159 year: 2005 ident: BFcmi201310_CR144 publication-title: Exp Hematol doi: 10.1016/j.exphem.2004.11.003 – volume: 11 start-page: 645 year: 2011 ident: BFcmi201310_CR34 publication-title: Nat Rev Immunol doi: 10.1038/nri3044 – volume: 53 start-page: 117 year: 1994 ident: BFcmi201310_CR88 publication-title: Urol Int doi: 10.1159/000282651 – volume: 11 start-page: 1097 year: 2004 ident: BFcmi201310_CR145 publication-title: Oncol Rep – volume: 99 start-page: 1259 year: 2002 ident: BFcmi201310_CR62 publication-title: Blood doi: 10.1182/blood.V99.4.1259 – volume: 113 start-page: 3735 year: 2009 ident: BFcmi201310_CR112 publication-title: Blood doi: 10.1182/blood-2008-10-182048 – volume: 7 start-page: 329 year: 2007 ident: BFcmi201310_CR46 publication-title: Nat Rev Immunol doi: 10.1038/nri2073 – volume: 51 start-page: 333 year: 2010 ident: BFcmi201310_CR194 publication-title: J Nucl Med doi: 10.2967/jnumed.109.061853 – volume: 358 start-page: 66 year: 1992 ident: BFcmi201310_CR28 publication-title: Nature doi: 10.1038/358066a0 – volume: 188 start-page: 1611 year: 1998 ident: BFcmi201310_CR51 publication-title: J Exp Med doi: 10.1084/jem.188.9.1611 – volume: 295 start-page: 2097 year: 2002 ident: BFcmi201310_CR101 publication-title: Science doi: 10.1126/science.1068440 – volume: 30A start-page: 1078 year: 1994 ident: BFcmi201310_CR96 publication-title: Eur J Cancer A doi: 10.1016/0959-8049(94)90460-X – volume: 25 start-page: 331 year: 2006 ident: BFcmi201310_CR20 publication-title: Immunity doi: 10.1016/j.immuni.2006.06.013 – volume: 128 start-page: 192 year: 2005 ident: BFcmi201310_CR186 publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2004.05286.x – volume: 10 start-page: 265 year: 2008 ident: BFcmi201310_CR142 publication-title: Cytotherapy doi: 10.1080/14653240801965156 – volume: 5 start-page: 259 year: 2003 ident: BFcmi201310_CR170 publication-title: Cytotherapy doi: 10.1080/14653240310001523 – volume: 25 start-page: 3514 year: 1995 ident: BFcmi201310_CR50 publication-title: Eur J Immunol doi: 10.1002/eji.1830251246 – volume: 7 start-page: 16 year: 2005 ident: BFcmi201310_CR132 publication-title: Cytotherapy doi: 10.1016/S1465-3249(05)70785-4 – volume: 90 start-page: 716 year: 1997 ident: BFcmi201310_CR106 publication-title: Blood doi: 10.1182/blood.V90.2.716 – volume: 110 start-page: 983 year: 2002 ident: BFcmi201310_CR113 publication-title: J Clin Invest doi: 10.1172/JCI0215950 – volume: 1 start-page: 41 year: 2001 ident: BFcmi201310_CR23 publication-title: Nat Rev Immunol doi: 10.1038/35095564 – volume: 50 start-page: 5421 year: 1990 ident: BFcmi201310_CR116 publication-title: Cancer Res – volume: 12 start-page: 1044 year: 2010 ident: BFcmi201310_CR169 publication-title: Cytotherapy doi: 10.3109/14653249.2010.504770 – volume: 9 start-page: 72 year: 2004 ident: BFcmi201310_CR4 publication-title: Drug Discov Today doi: 10.1016/S1359-6446(03)02955-6 – volume: 19 start-page: 561 year: 2003 ident: BFcmi201310_CR73 publication-title: Immunity doi: 10.1016/S1074-7613(03)00264-4 – volume: 175 start-page: 5095 year: 2005 ident: BFcmi201310_CR162 publication-title: J Immunol doi: 10.4049/jimmunol.175.8.5095 – volume: 47 start-page: 5725 year: 1987 ident: BFcmi201310_CR65 publication-title: Cancer Res – volume: 408 start-page: 57 year: 2000 ident: BFcmi201310_CR117 publication-title: Nature doi: 10.1038/35040504 – volume: 92 start-page: 4248 year: 1998 ident: BFcmi201310_CR55 publication-title: Blood doi: 10.1182/blood.V92.11.4248 – volume: 106 start-page: 376 year: 2005 ident: BFcmi201310_CR150 publication-title: Blood doi: 10.1182/blood-2004-12-4797 – volume: 5 start-page: 112 year: 1975 ident: BFcmi201310_CR15 publication-title: Eur J Immunol doi: 10.1002/eji.1830050208 – volume: 11 start-page: 5984 year: 2005 ident: BFcmi201310_CR123 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-0577 – volume: 27 start-page: 5932 year: 2008 ident: BFcmi201310_CR31 publication-title: Oncogene doi: 10.1038/onc.2008.267 – volume: 29 start-page: 104 year: 2001 ident: BFcmi201310_CR156 publication-title: Exp Hematol doi: 10.1016/S0301-472X(00)00617-2 – volume: 134 start-page: 4267 year: 1985 ident: BFcmi201310_CR67 publication-title: J Immunol doi: 10.4049/jimmunol.134.6.4267 – volume: 12 start-page: 500 issue: 6 year: 2011 ident: BFcmi201310_CR33 publication-title: Nature Immunology doi: 10.1038/ni.2032 – volume: 178 start-page: 4011 year: 2007 ident: BFcmi201310_CR95 publication-title: J Immunol doi: 10.4049/jimmunol.178.7.4011 – volume: 180 start-page: 6392 year: 2008 ident: BFcmi201310_CR124 publication-title: J Immunol doi: 10.4049/jimmunol.180.9.6392 – volume: 26 start-page: 1113 year: 2006 ident: BFcmi201310_CR2 publication-title: Anticancer Res – volume: 115 start-page: 442 year: 2001 ident: BFcmi201310_CR87 publication-title: Br J Haematol doi: 10.1046/j.1365-2141.2001.03055.x – volume: 202 start-page: 1075 year: 2005 ident: BFcmi201310_CR86 publication-title: J Exp Med doi: 10.1084/jem.20051511 – volume: 70 start-page: 83 year: 1998 ident: BFcmi201310_CR66 publication-title: Adv Immunol doi: 10.1016/S0065-2776(08)60387-9 – volume: 11 start-page: 237 year: 1990 ident: BFcmi201310_CR49 publication-title: Immunol Today doi: 10.1016/0167-5699(90)90097-S – volume: 369 start-page: 31 year: 1994 ident: BFcmi201310_CR53 publication-title: Nature doi: 10.1038/369031a0 – volume: 3 start-page: 501 year: 1984 ident: BFcmi201310_CR85 publication-title: J Biol Response Mod – volume: 16 start-page: 1107 year: 2010 ident: BFcmi201310_CR178 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2010.02.018 – volume: 33 start-page: 1160 year: 2005 ident: BFcmi201310_CR134 publication-title: Exp Hematol doi: 10.1016/j.exphem.2005.06.024 – volume: 29 start-page: 134 year: 2010 ident: BFcmi201310_CR199 publication-title: J Exp Clin Cancer Res doi: 10.1186/1756-9966-29-134 – volume: 93 start-page: 1612 year: 1999 ident: BFcmi201310_CR70 publication-title: Blood doi: 10.1182/blood.V93.5.1612 – volume: 17 start-page: 6287 year: 2011 ident: BFcmi201310_CR176 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-1347 – volume: 42 start-page: 128 year: 2008 ident: BFcmi201310_CR137 publication-title: Cytokine doi: 10.1016/j.cyto.2008.01.003 – volume: 10 start-page: 5027 year: 2004 ident: BFcmi201310_CR114 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-0265 – volume: 9 start-page: 193 year: 2012 ident: BFcmi201310_CR16 publication-title: Cell Mol Immunol doi: 10.1038/cmi.2012.8 – volume: 6 start-page: 56 year: 2012 ident: BFcmi201310_CR126 publication-title: Front Med doi: 10.1007/s11684-012-0177-7 – volume: 195 start-page: 327 year: 2002 ident: BFcmi201310_CR77 publication-title: J Exp Med doi: 10.1084/jem.20010938 – volume: 11 start-page: 658 year: 2011 ident: BFcmi201310_CR180 publication-title: Nat Rev Immunol doi: 10.1038/nri3065 – volume: 86 start-page: 209 year: 2005 ident: BFcmi201310_CR82 publication-title: Adv Immunol doi: 10.1016/S0065-2776(04)86006-1 – volume: 167 start-page: 2068 year: 2001 ident: BFcmi201310_CR56 publication-title: J Immunol doi: 10.4049/jimmunol.167.4.2068 – volume: 109 start-page: 3603 year: 2007 ident: BFcmi201310_CR105 publication-title: Blood doi: 10.1182/blood-2006-05-024315 – volume: 5 start-page: e9221 year: 2010 ident: BFcmi201310_CR154 publication-title: PLoS One doi: 10.1371/journal.pone.0009221 – volume: 29 start-page: 1390 year: 1999 ident: BFcmi201310_CR68 publication-title: Eur J Immunol doi: 10.1002/(SICI)1521-4141(199904)29:04<1390::AID-IMMU1390>3.0.CO;2-C – volume: 28 start-page: 175 year: 2005 ident: BFcmi201310_CR102 publication-title: J Immunother doi: 10.1097/01.cji.0000161395.88959.1f – volume: 83 start-page: 2594 year: 1994 ident: BFcmi201310_CR157 publication-title: Blood doi: 10.1182/blood.V83.9.2594.2594 – volume: 2 start-page: 35 year: 2002 ident: BFcmi201310_CR5 publication-title: Expert Opin Biol Ther doi: 10.1517/14712598.2.1.35 – volume: 8 start-page: 433 year: 2011 ident: BFcmi201310_CR32 publication-title: Cell Mol Immunol doi: 10.1038/cmi.2011.20 – volume: 105 start-page: 3051 year: 2005 ident: BFcmi201310_CR103 publication-title: Blood doi: 10.1182/blood-2004-07-2974 – volume: 16 start-page: 216 year: 1975 ident: BFcmi201310_CR14 publication-title: Int J Cancer doi: 10.1002/ijc.2910160204 – volume: 40 start-page: 84 year: 2008 ident: BFcmi201310_CR172 publication-title: Blood Cells Mol Dis doi: 10.1016/j.bcmd.2007.06.029 – volume: 24 start-page: 406 year: 1996 ident: BFcmi201310_CR136 publication-title: Exp Hematol – volume: 66 start-page: 2520 year: 2006 ident: BFcmi201310_CR9 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-2520 – volume: 57 start-page: 1541 year: 2008 ident: BFcmi201310_CR133 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-008-0492-7 – volume: 106 start-page: 12879 year: 2009 ident: BFcmi201310_CR184 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0901653106 – reference: 9226172 - Blood. 1997 Jul 15;90(2):716-25 – reference: 17999637 - Stem Cells Dev. 2007 Dec;16(6):1043-51 – reference: 19837059 - Eur J Pharmacol. 2009 Dec 25;625(1-3):41-54 – reference: 16115943 - Clin Cancer Res. 2005 Aug 15;11(16):5984-92 – reference: 15531883 - Nat Immunol. 2004 Dec;5(12):1260-5 – reference: 15705423 - Adv Immunol. 2005;86:209-39 – reference: 16860661 - Adv Cancer Res. 2006;95:293-322 – reference: 15297404 - Clin Cancer Res. 2004 Aug 1;10(15):5027-37 – reference: 15632206 - Blood. 2005 Apr 15;105(8):3051-7 – reference: 1313126 - Leukemia. 1992 Feb;6(2):136-41 – reference: 21844012 - Clin Cancer Res. 2011 Oct 1;17(19):6287-97 – reference: 17717662 - Cancer Immunol Immunother. 2008 Mar;57(3):411-23 – reference: 18280748 - Cytokine. 2008 Apr;42(1):128-36 – reference: 17371953 - J Immunol. 2007 Apr 1;178(7):4011-6 – reference: 11743585 - Nat Immunol. 2002 Jan;3(1):83-90 – reference: 16408158 - Cancer Metastasis Rev. 2005 Dec;24(4):487-99 – reference: 15173076 - Clin Cancer Res. 2004 Jun 1;10(11):3699-707 – reference: 21946842 - Nat Rev Clin Oncol. 2011 Nov;8(11):677-88 – reference: 11830474 - Blood. 2002 Feb 15;99(4):1259-66 – reference: 11535826 - Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10716-21 – reference: 16040380 - Cytotherapy. 2005;7(1):16-22 – reference: 8599969 - Exp Hematol. 1996 Feb;24(3):406-15 – reference: 19923897 - Cancer Biol Ther. 2009 Dec;8(23):2211-20 – reference: 15676209 - Exp Hematol. 2005 Feb;33(2):159-64 – reference: 21035183 - Biomaterials. 2011 Feb;32(4):1167-76 – reference: 12370276 - J Clin Invest. 2002 Oct;110(7):983-92 – reference: 11960290 - Cancer Gene Ther. 2002 Apr;9(4):390-8 – reference: 14764669 - J Immunol. 2004 Feb 15;172(4):2048-58 – reference: 21822297 - Cell Mol Immunol. 2012 Jan;9(1):45-53 – reference: 16782653 - Int J Radiat Biol. 2006 May;82(5):355-61 – reference: 19553639 - Blood. 2009 Sep 24;114(13):2667-77 – reference: 22460449 - Front Med. 2012 Mar;6(1):56-66 – reference: 1234049 - Eur J Immunol. 1975 Feb;5(2):112-7 – reference: 18317755 - Cancer Immunol Immunother. 2008 Oct;57(10):1541-52 – reference: 15757378 - Expert Opin Biol Ther. 2005 Feb;5(2):163-72 – reference: 21941294 - Nat Rev Immunol. 2011 Oct;11(10):658-71 – reference: 11900991 - Cytokine Growth Factor Rev. 2002 Apr;13(2):155-68 – reference: 20169160 - PLoS One. 2010;5(2):e9221 – reference: 11135622 - Nat Med. 2001 Jan;7(1):94-100 – reference: 6292259 - J Clin Immunol. 1982 Oct;2(4):249-63 – reference: 17964828 - Blood Cells Mol Dis. 2008 Jan-Feb;40(1):84-90 – reference: 11522236 - J Hematother Stem Cell Res. 2001 Aug;10(4):535-44 – reference: 2386946 - Cancer Res. 1990 Sep 1;50(17):5421-5 – reference: 8643653 - Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1453-7 – reference: 11602317 - Exp Hematol. 2001 Oct;29(10):1157-68 – reference: 9573023 - Blood. 1998 May 15;91(10):3850-61 – reference: 19109559 - Blood. 2009 Apr 16;113(16):3735-43 – reference: 15933055 - Blood. 2005 Oct 1;106(7):2252-8 – reference: 21869816 - Nat Rev Immunol. 2011 Oct;11(10):645-57 – reference: 20703455 - Cancer Immunol Immunother. 2010 Dec;59(12):1781-9 – reference: 8566046 - Eur J Immunol. 1995 Dec;25(12):3514-6 – reference: 19614820 - J Intern Med. 2009 Aug;266(2):154-81 – reference: 15546400 - Immunol Rev. 2004 Dec;202:275-93 – reference: 17100877 - Immunol Rev. 2006 Dec;214:73-91 – reference: 11750709 - Lung Cancer. 2002 Jan;35(1):23-8 – reference: 20201786 - Curr Cancer Drug Targets. 2010 Mar;10(2):200-9 – reference: 11133760 - Blood. 2001 Jan 1;97(1):192-7 – reference: 11698225 - Trends Immunol. 2001 Nov;22(11):633-40 – reference: 16901727 - Immunity. 2006 Aug;25(2):331-42 – reference: 18418772 - Cytotherapy. 2008;10(3):265-74 – reference: 9191519 - Cancer. 1997 Jun 15;79(12):2320-8 – reference: 19483647 - J Immunother. 2009 Jul-Aug;32(6):622-31 – reference: 11257133 - J Exp Med. 2001 Mar 19;193(6):661-70 – reference: 21644031 - Cancer Immunol Immunother. 2011 Aug;60(8):1195-205 – reference: 9834230 - Blood. 1998 Dec 1;92(11):4248-55 – reference: 20491532 - Cytotherapy. 2010 Oct;12(6):750-63 – reference: 16698441 - Hum Immunol. 2006 Mar;67(3):188-95 – reference: 10784373 - Int J Clin Lab Res. 1999;29(4):135-40 – reference: 12847225 - J Immunol. 2003 Jul 15;171(2):608-15 – reference: 2201309 - Immunol Today. 1990 Jul;11(7):237-44 – reference: 17068155 - Blood. 2007 Mar 1;109(5):2008-13 – reference: 20801411 - Transl Res. 2010 Sep;156(3):147-54 – reference: 10029590 - Blood. 1999 Mar 1;93(5):1612-21 – reference: 10685650 - Cancer J Sci Am. 2000 Feb;6 Suppl 1:S2-7 – reference: 21669033 - Cell Transplant. 2011;20(11-12):1731-46 – reference: 11801676 - J Immunol. 2002 Feb 1;168(3):1356-61 – reference: 15367431 - Blood. 2005 Jan 15;105(2):721-7 – reference: 22900959 - Cytotherapy. 2012 Oct;14(9):1131-43 – reference: 50294 - Int J Cancer. 1975 Aug 15;16(2):216-29 – reference: 10649250 - Cancer. 2000 Feb 1;88(3):577-83 – reference: 3951539 - Nature. 1986 Feb 20-26;319(6055):675-8 – reference: 20795758 - Cytotherapy. 2010 Dec;12(8):1044-55 – reference: 20849361 - Cytotherapy. 2011 Jan;13(1):98-107 – reference: 16376102 - Semin Cancer Biol. 2006 Apr;16(2):115-23 – reference: 9209739 - Biol Blood Marrow Transplant. 1997 Apr;3(1):34-44 – reference: 3903508 - N Engl J Med. 1985 Dec 5;313(23):1485-92 – reference: 16619514 - Anticancer Res. 2006 Mar-Apr;26(2A):1113-34 – reference: 9755338 - Adv Immunol. 1998;70:83-243 – reference: 19365083 - Blood. 2009 Jun 11;113(24):6094-101 – reference: 7654433 - Eur J Cancer. 1994;30A(8):1078-83 – reference: 11828007 - J Exp Med. 2002 Feb 4;195(3):327-33 – reference: 12838283 - Bone Marrow Transplant. 2003 Jul;32(2):177-86 – reference: 20937115 - J Exp Clin Cancer Res. 2010;29:134 – reference: 11489989 - J Immunol. 2001 Aug 15;167(4):2068-73 – reference: 12415255 - Nat Rev Cancer. 2002 Nov;2(11):850-61 – reference: 9694726 - Blood. 1998 Aug 15;92(4):1374-83 – reference: 3877776 - J Exp Med. 1985 Dec 1;162(6):1745-59 – reference: 1286165 - Semin Immunol. 1992 Dec;4(6):379-88 – reference: 8164737 - Nature. 1994 May 5;369(6475):31-7 – reference: 7645136 - Urol Int. 1994;53(3):117-24 – reference: 12370336 - J Immunol. 2002 Oct 15;169(8):4098-102 – reference: 10694580 - Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2731-6 – reference: 17979846 - Immunol Rev. 2007 Dec;220:169-82 – reference: 11772338 - Expert Opin Biol Ther. 2002 Jan;2(1):35-43 – reference: 19383914 - Cancer Res. 2009 May 1;69(9):4010-7 – reference: 23063974 - Int Immunopharmacol. 2012 Dec;14(4):593-605 – reference: 10803526 - Leukemia. 2000 May;14(5):922-30 – reference: 18425107 - Nat Immunol. 2008 May;9(5):503-10 – reference: 3989307 - J Immunol. 1985 Jun;134(6):4267-75 – reference: 10352283 - J Immunol. 1999 Jun 1;162(11):6658-62 – reference: 15153474 - J Immunol. 2004 Jun 1;172(11):6598-606 – reference: 21248148 - J Leukoc Biol. 2011 Apr;89(4):625-38 – reference: 18836917 - Cytotherapy. 2008;10(6):625-32 – reference: 6154658 - Int J Cancer. 1980 Apr 15;25(4):475-86 – reference: 18836474 - Oncogene. 2008 Oct 6;27(45):5932-43 – reference: 22705914 - Cell Mol Immunol. 2012 Jul;9(4):310-20 – reference: 18829563 - Cancer Res. 2008 Oct 1;68(19):8049-57 – reference: 3499218 - Cancer Res. 1987 Nov 1;47(21):5725-32 – reference: 19650714 - Crit Rev Clin Lab Sci. 2009;46(4):167-89 – reference: 16510567 - Cancer Res. 2006 Mar 1;66(5):2520-6 – reference: 7923250 - Cancer Immunol Immunother. 1994 Sep;39(3):193-7 – reference: 19561305 - Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84 – reference: 19308771 - Cytotherapy. 2009;11(3):341-55 – reference: 19717293 - Curr Opin Immunol. 2009 Oct;21(5):525-30 – reference: 18424763 - J Immunol. 2008 May 1;180(9):6392-401 – reference: 20563804 - Cancer Immunol Immunother. 2010 Oct;59(10):1511-9 – reference: 10415049 - J Immunol. 1999 Aug 1;163(3):1473-80 – reference: 14563320 - Immunity. 2003 Oct;19(4):561-9 – reference: 20631071 - Cancer Res. 2010 Aug 1;70(15):6109-13 – reference: 10781403 - Curr Opin Immunol. 2000 Jun;12(3):323-9 – reference: 16551250 - Annu Rev Immunol. 2006;24:257-86 – reference: 21660134 - J Biomed Biotechnol. 2011;2011:379123 – reference: 6389777 - J Biol Response Mod. 1984 Oct;3(5):501-11 – reference: 15638853 - Br J Haematol. 2005 Jan;128(2):192-203 – reference: 8625188 - Cancer. 1995 Sep 1;76(5):840-52 – reference: 14685783 - Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):403-7 – reference: 8639878 - Blood. 1996 Apr 1;87(7):2632-40 – reference: 6863925 - J Immunol. 1983 Aug;131(2):1024-7 – reference: 1614533 - Nature. 1992 Jul 2;358(6381):66-70 – reference: 21739673 - Nat Immunol. 2011 Jun;12(6):500-8 – reference: 11117911 - Lancet. 2000 Nov 25;356(9244):1795-9 – reference: 21791425 - Blood. 2011 Sep 22;118(12):3273-9 – reference: 19682859 - J Autoimmun. 2009 Nov-Dec;33(3-4):275-81 – reference: 18506449 - Eur Radiol. 2008 Oct;18(10):2021-32 – reference: 16210613 - J Immunol. 2005 Oct 15;175(8):5095-103 – reference: 15841099 - Nat Rev Immunol. 2005 May;5(5):363-74 – reference: 11164111 - Exp Hematol. 2001 Jan;29(1):104-13 – reference: 7513206 - Blood. 1994 May 1;83(9):2594-601 – reference: 15020274 - Haematologica. 2004 Mar;89(3):338-47 – reference: 11703348 - Br J Haematol. 2001 Nov;115(2):442-50 – reference: 21193697 - Blood. 2011 Feb 24;117(8):2423-32 – reference: 20188202 - Biol Blood Marrow Transplant. 2010 Aug;16(8):1107-14 – reference: 15661266 - Leuk Res. 2005 Mar;29(3):301-6 – reference: 10687148 - J Immunother. 2000 Jan;23(1):154-60 – reference: 17438573 - Nat Rev Immunol. 2007 May;7(5):329-39 – reference: 12850795 - Cytotherapy. 2003;5(3):259-72 – reference: 11081504 - Nature. 2000 Nov 2;408(6808):57-63 – reference: 9766501 - Leukemia. 1998 Oct;12(10):1565-72 – reference: 20171010 - Pain. 2010 Apr;149(1):135-42 – reference: 9802973 - J Exp Med. 1998 Nov 2;188(9):1611-9 – reference: 19344572 - Mol Imaging. 2009 Jan-Feb;8(1):15-26 – reference: 22020068 - Cell Mol Immunol. 2012 Jan;9(1):11-9 – reference: 15274367 - Anticancer Res. 2004 May-Jun;24(3b):1861-71 – reference: 12536241 - Cancer Immunol Immunother. 2003 Jan;52(1):59-64 – reference: 20150252 - J Nucl Med. 2010 Mar;51(3):333-6 – reference: 14710949 - Adv Cancer Res. 2003;90:127-56 – reference: 11340575 - Int J Cancer. 2001 Jun 1;92(5):697-702 – reference: 8142149 - Eur J Cancer. 1994;30A(1):103-5 – reference: 11905830 - Nat Rev Immunol. 2001 Dec;1(3):209-19 – reference: 12400646 - J Small Anim Pract. 2002 Oct;43(10):464-7 – reference: 16230475 - J Exp Med. 2005 Oct 17;202(8):1075-85 – reference: 2437198 - J Immunol. 1987 May 15;138(10):3566-72 – reference: 15838373 - J Immunother. 2005 May-Jun;28(3):175-82 – reference: 10339496 - Blood. 1999 Jun 1;93(11):3876-84 – reference: 10438925 - J Immunol. 1999 Aug 15;163(4):1906-13 – reference: 17179231 - Blood. 2007 Apr 15;109(8):3603-6 – reference: 22279576 - PLoS One. 2012;7(1):e30264 – reference: 19652198 - Blood. 2009 Oct 22;114(17):3513-23 – reference: 21706044 - Cell Mol Immunol. 2011 Sep;8(5):433-40 – reference: 15012931 - Drug Discov Today. 2004 Jan 15;9(2):72-81 – reference: 20670353 - Tissue Antigens. 2010 Dec;76(6):467-75 – reference: 12149207 - Blood. 2002 Aug 15;100(4):1265-73 – reference: 10365666 - Hum Gene Ther. 1999 May 20;10(8):1359-73 – reference: 22504953 - Cell Mol Immunol. 2012 May;9(3):193-4 – reference: 14734707 - J Immunol. 2004 Feb 1;172(3):1333-9 – reference: 15069553 - Oncol Rep. 2004 May;11(5):1097-106 – reference: 11905813 - Nat Rev Immunol. 2001 Oct;1(1):41-9 – reference: 10229107 - Eur J Immunol. 1999 Apr;29(4):1390-6 – reference: 19548853 - Expert Opin Investig Drugs. 2009 Jul;18(7):991-1000 – reference: 15464915 - Adv Pharmacol. 2004;51:295-318 – reference: 7716543 - Science. 1995 Apr 21;268(5209):405-8 – reference: 356546 - Adv Cancer Res. 1978;27:305-77 – reference: 16219538 - Exp Hematol. 2005 Oct;33(10):1160-71 – reference: 11828008 - J Exp Med. 2002 Feb 4;195(3):335-41 – reference: 21698239 - PLoS One. 2011;6(6):e20740 – reference: 11896281 - Science. 2002 Mar 15;295(5562):2097-100 – reference: 11986221 - Blood. 2002 May 15;99(10):3661-7 – reference: 15755898 - Blood. 2005 Jul 1;106(1):376-83 |
| SSID | ssj0058474 |
| Score | 2.5324376 |
| SecondaryResourceType | review_article |
| Snippet | Natural killer （NK） cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce... Natural killer (NK) cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce... Natural killer (NK) cells play critical roles in host immunity against cancer, hi response, cancers develop mechanisms to escape NK cell attack or induce... |
| SourceID | pubmedcentral proquest pubmed crossref springer chongqing |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 230 |
| SubjectTerms | Adoptive transfer Animals Antibodies Antigens Autoantigens Autografts Biomedical and Life Sciences Biomedicine Blood cells Cancer Cancer immunotherapy Cell Proliferation Cell therapy Clinical trials Clinical Trials as Topic Cord blood Fc receptors Good Manufacturing Practice Growth factors Histocompatibility Humans Immunity, Cellular - immunology Immunology Immunotherapy Inhibitory postsynaptic potentials Killer Cells, Natural - immunology Medical Microbiology Microbiology Natural killer cells Neoplasms - immunology Neoplasms - therapy NK细胞 Paralysis Pluripotency Quality control Review Stem cells Tumors Vaccine 免疫治疗 免疫疗法 基础 多能干细胞 恶性 疾病 自然杀伤细胞 |
| Title | NK cell-based immunotherapy for malignant diseases |
| URI | http://lib.cqvip.com/qk/87787X/201303/46125738.html https://link.springer.com/article/10.1038/cmi.2013.10 https://www.ncbi.nlm.nih.gov/pubmed/23604045 https://www.proquest.com/docview/1785511029 https://www.proquest.com/docview/2760385158 https://www.proquest.com/docview/1349092831 https://www.proquest.com/docview/1434036203 https://pubmed.ncbi.nlm.nih.gov/PMC4076738 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEA_2iuiL-O3VeqxQX4S1u5l87D6JSktROEQs3NuSzUd7YPda7_rQ_96ZXHb1vNLHZULI_pLM_JKZyTB2ECpwzto2117hAcWYIjcF-NxLWyrfmta4GCA7VSen4utMztKF2zKFVfY6MSpqt7B0R35IVeSRHBS8_nh5lVPVKPKuphIaO2wXVXAlR2z389H0-49eF5MPMPqVlUYeqaoyZegVUB3aizlFdsEHSp59gLqmO7tCa7Fpn7ZI53bs5H8O1GiXjh-zR4lQZp_WK-AJu-e7p-z-usTkzTPGp98yupzPyVy5bE7pICnp6iZDwppdIBE_o2iYLPlqls_Z6fHRzy8neaqTkFska6ucB2lwKjiauxoC6FZLNNq1kyCB2xKML4JpHWjEXfMigAvSqtrz2oZStBZesFG36PwrlmlulHJGBdE6gb1WUtc4f4AsUNigqzHbG5BqLtfvYTSCWJIGFL7voWtsemGcCl38aqKnG6oGMW8Ic_was4Ohcd_Rrc32-zlo0u5aNn_Xwq1irhX5O0uJI3o7iHHbENym84tr7AJEXdTIrco72ggQZOALGLOX61kfhspBofoTcsz0xnoYGtCz3ZuSbn4en-_GI7SKaL3rV84_f7aNwN7dCLxmD3ms0EExmPtstPp97d8gT1q1E7ajZ3qStsQkXmT9AZjAFNQ |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LTxRBEO4gxODF-IRF0DGBi8nITFc_Zg7GoEIWFzfGQMJt6OnuwU1kFtwlZv-Uv9Gqeem6hBvHTXc6PV_X4-utqi7GtosEnLM2D7VXeEExJgpNBD700sbK5yY3rkqQHar-ifh8Kk-X2O-2FobSKlubWBlqN7b0H_kudZFHchDx9P3lVUhdoyi62rbQqMVi4Ge_8Mo2eXf4Cc93h_OD_eOP_bDpKhBapDbTkBfS4MY5OocUCtC5lujiUidBArcxGB8VJnegcZeaRwW4QlqVep7aIha5BVz3HltBmpGiFq182B9-_dbafoo5VnFspZG3qiRuKgIjSHbtxYgyyeAtFeuuom0rz6_QO837wwWSu5ir-V_AtvKDB4_Yw4bABnu1xD1mS758wu7XLS1nTxkfDgIKBoTkHl0wovKTpshrFiBBDi6Q-J9T9k3QxIYmz9jJnSD4nC2X49Kvs0Bzo5QzqhC5E7hqInWK8gLIOoUtdNJjGx1S2WX9_kYmiJVpwME3LXSZbV40p8YaP7Iqsg5JhphnhDn-6rHtbnK70I3TNtszyBptnmR_Ze_GYa4VxVdjiTt63Q2jmhLcpvTja1wCRBqlyOXiW-YIEEQoIuixtfrUu61yUGhuhewxPScP3QR6Jnx-pBx9r54Lxyu7qtDaaSXnny9bRGDjdgResdX-8Zej7OhwOHjBHvCqOwjlf26y5enPa7-FHG2av2wUI2Bnd62LfwB9BlFs |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrXhcEO9uKRCk9oIUNrEdOzkgBLSrlkWrClGpt-D4UVZqsy27Fdq_xq9jJi9Ytuqtx8iWZX-e8XzOzHgAtn3KrTWmCJWTeEHROgp1xF3oEhNLV-hC2ypAdiz3j8Tn4-R4DX63uTAUVtmeidVBbaeG_pEPqIo8koOIZQPfhEUc7g7fn1-EVEGKPK1tOY1aREZu8Quvb7N3B7u41zuMDfe-fdoPmwoDoUGaMw-ZTzQugqGhyLjnqlAJmrvMJjzhzMRcu8jrwnKFM1Ys8tz6xMjMscz4WBSG47i3YF2hVUx7sP5xb3z4tbUD5H-sfNpSIYeVadxkB0Y8HZizCUWV8beUuHsXz7ny5AIt1bJtXCG8q3Gb_zlvK5s4fAD3GzIbfKil7yGsufIR3K7LWy4eAxuPAnIMhGQqbTChVJQm4WsRIFkOzvAScEKROEHjJ5o9gaMbQfAp9Mpp6TYgUExLabX0orACR00TlaHscGSgwniV9mGzQyo_r9_iyAUxNMWx8U0LXW6a182pyMZpXnnZeZoj5jlhjl992O46twNd2W2r3YO80exZ_lcOr2xmSpKvNU5wRq-7ZlRZgluXbnqJQ3CRRRnyuviaPoILIhcR78Ozete7qTIu8egVSR_Ukjx0HejJ8OWWcvKjejocr--yQmunlZx_VraKwOb1CLyCO6iD-ZeD8eg53GNVoRAKBd2C3vznpXuBdG1evGz0IoDvN62KfwD9LVWY |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=NK+cell-based+immunotherapy+for+malignant+diseases&rft.jtitle=Cellular+%26+molecular+immunology&rft.au=Cheng%2C+Min&rft.au=Chen%2C+Yongyan&rft.au=Xiao%2C+Weihua&rft.au=Sun%2C+Rui&rft.date=2013-05-01&rft.eissn=2042-0226&rft.volume=10&rft.issue=3&rft.spage=230&rft_id=info:doi/10.1038%2Fcmi.2013.10&rft_id=info%3Apmid%2F23604045&rft.externalDocID=23604045 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F87787X%2F87787X.jpg |